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A B S T R A C T
Background
Many patients with cancer experience moderate to severe pain that requires treatment with strong analgesics. Buprenorphine, fentanyl
and morphine are examples of strong opioids used for the relief of cancer pain. Strong opioids are, however, not effective for pain in all
patients nor are they well-tolerated by all patients. The aim of this Cochrane review is to assess whether buprenorphine is associated
with superior, inferior or equal pain relief and tolerability compared to other analgesic options for patients with cancer pain.
Objectives
To assess the effectiveness and tolerability of buprenorphine for pain in adults and children with cancer.
Search methods
We searched CENTRAL (the Cochrane Library) issue 12 or 12 2014, MEDLINE (via OVID) 1948 to 20 January 2015, EMBASE (via
OVID) 1980 to20 January 2015, ISIWebof Science (SCI-EXPANDED&CPCI-S) to 20 January 2015, ISIBIOSIS 1969 to 20 January
2015. We also searched ClinicalTrials.gov (http://clinicaltrials.gov/;metaRegister of Controlled Trials (mRCT) (http://www.controlled-
trials.com/mrct/), theWorld Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal (http:
//apps.who.int/trialsearch/) and the Proceedings of the Congress of the European Federation of International Association for the Study
of Pain (IASP; via European Journal of Pain Supplements) on 16 February 2015. We checked the bibliographic references of identified
studies as well as relevant studies and systematic reviews to find additional trials not identified by the electronic searches. We contacted
authors of included studies for other relevant studies.
Selection criteria
We included randomised controlled trials, with parallel-group or crossover design, comparing buprenorphine (any formulation and any
route of administration) with placebo or an active drug (including buprenorphine) for cancer background pain in adults and children.
Data collection and analysis
Two review authors independently extracted data pertaining to study design, participant details (including age, cancer characteristics,
previous analgesic medication and setting), interventions (including details about titration) and outcomes, and independently assessed
the quality of the included studies according to standard Cochrane methodology. As it was not feasible to meta-analyse the data, we
summarised the results narratively. We assessed the overall quality of the evidence for each outcome using the GRADE approach.
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Main results
In this Cochrane review we identified 19 relevant studies including a total of 1421 patients that examined 16 different intervention
comparisons.
Of the studies that compared buprenorphine to another drug, 11 studies performed comparative analyses between the randomised
groups, and five studies found that buprenorphine was superior to the comparison treatment. Three studies found no differences
between buprenorphine and the comparison drug, while another three studies found treatment with buprenorphine to be inferior to
the alternative treatment in terms of the side effects profile or patients preference/acceptability.
Of the studies that compared different doses or formulations/routes of administration of buprenorphine, pain intensity ratings did not
differ significantly between intramuscular buprenorphine and buprenorphine suppository. However, the average severity of dizziness,
nausea, vomiting and adverse events as a total were all significantly higher in the intramuscular group relatively to the suppository group
(one study).
Sublingual buprenorphine was associated with faster onset of pain relief compared to subdermal buprenorphine, with similar duration
analgesia and no significant differences in adverse event rates reported between the treatments (one study).
In terms of transdermal buprenorphine, two studies found it superior to placebo, whereas a third study found no difference between
placebo and different doses of transdermal buprenorphine.
The studies that examined different doses of transdermal buprenorphine did not report a clear dose-response relationship.
The quality of this evidence base was limited by under-reporting of most bias assessment items (e.g., the patient selection items), by
small sample sizes in several included studies, by attrition (with data missing from 8.2% of the enrolled/randomised patients for efficacy
and from 14.6% for safety) and by limited or no reporting of the expected outcomes in a number of cases. The evidence for all the
outcomes was very low quality.
Authors’ conclusions
Based on the available evidence, it is difficult to say where buprenorphine fits in the treatment of cancer pain with strong opioids.
However, it might be considered to rank as a fourth-line option compared to the more standard therapies of morphine, oxycodone
and fentanyl, and even there it would only be suitable for some patients. However, palliative care patients are often heterogeneous and
complex, so having a number of analgesics available that can be given differently increases patient and prescriber choice. In particular,
the sublingual and injectable routes seemed to have a more definable analgesic effect, whereas the transdermal route studies left more
questions.
P L A I N L A N G U A G E S U M M A R Y
Buprenorphine for treating people with cancer pain
Buprenorphine produced good pain relief for most people with moderate or severe cancer pain, but its role in the treatment of cancer
pain is still unclear.
Many patients with cancer experience moderate-to-severe pain that requires treatment with strong pain relief medicines. Buprenorphine
and morphine are examples of strong pain relief medicines that are used for the relief of cancer pain. However, strong pain relief
medicines are not effective for pain in all patients nor are they well-tolerated by all patients. The aim of this Cochrane review is to assess
whether buprenorphine is associated with better, worse or equal pain relief and tolerability compared to other pain relief medicines for
patients with cancer pain.
We searched the literature on 20 Janurary 2015 and found 19 relevant studies with a total of 1421 patients that compared different
types of buprenorphine to each other or to other strong pain relief medicines or to placebo. The reported average ages of the patients
ranged from 49.1 years to 67.16 years, and the duration of the studies ranged from single dose treatment to six months.
Generally, the studies showed that buprenorphine is an effective strong pain relief medicine that in some cases may be slightly better
than other strong pain relief medicines. However, the evidence provided by these studies were of very low quality and on the basis of the
available evidence, it is still hard to say where buprenorphine fits in in the treatment of cancer pain with strong opioids. All the strong
pain relief medicines examined in the studies are also associated with a number of unwanted effects, such as vomiting, constipation
and drowsiness.
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B A C K G R O U N D
Description of the condition
Pain affects approximately 75% of people with advanced cancer
(Deandra 2008). According to the World Health Organization
(WHO), the incidence of cancer was just under 12.7 million new
cases in 2008 and is estimated to reach over 15 million cases in
2020 (Ferlay 2010; Frankish 2003). Unrelieved cancer pain is a
cause of major suffering worldwide. Globally, millions of people
suffer from unrelieved pain, particularly in low- and middle-in-
come countries (World Bank 2013) where cancer is diagnosed in
late stages when pain is often severe (Seya 2011; Ferlay 2010). Es-
timates of cancer pain prevalence vary widely. This has been due
in part to a lack of standardisation in the definition of pain and
the measures used to assess it, and because of the heterogeneity of
cancer diagnoses. There is also heterogeneity in terms of where and
in what setting patients with cancer and cancer pain receive their
treatments (e.g., in outpatient clinics, in hospitals or in day units).
In general, prevalence of pain at the time of cancer diagnosis and
early in the course of disease is thought to be approximately 50%,
increasing to 75% in the more advanced stages (Portenoy 1989).
According to a systematic review, pain prevalence ranges from33%
in patients after curative cancer treatment, to 59% in patients on
anticancer treatment and to 64% in patients with metastatic, ad-
vanced or terminal phase disease (van den Beuken-van Everdingen
2007).
Cancer pain may be acute and chronic and is divided into four
physiological types: nociceptive (somatic or visceral), neuropathic
and sympathetically maintained pain (Foley 1998). Each of these
pain types can result from the tumour itself causing compression
or infiltration, or it may be more indirectly related to the cancer
and its treatments, e.g., constipation, muscle spasms, post-surgi-
cal scars or lymphoedema. Patients with cancer may have painful
concurrent disorders which may be exacerbated by the presence of
the cancer, e.g., osteoarthritis.
Description of the intervention
Buprenorphine is prescribed in the management of cancer pain,
but is not a typical first-line opioid. However, it is starting to
experience a renaissance in themanagement of both chronic cancer
and non-cancer pain and it is also used in people with opioid-
dependence (Foster 2013).
The WHO classifies buprenorphine as a step III opioid analgesic
(WHO 1996). It has mixed agonistic and antagonistic properties.
Its opioid agonistic activity is exerted on µ-opioid receptors and
theORL-1 receptor, whilst it is a kappa- and delta-opioid receptor
antagonist (Lewis 2004; Rothman 1995; Zaki 2000). It is given
either transdermally (via a patch), as an injection or via the oral
mucosa (sublingually). Mainly metabolised by the liver, buprenor-
phine goes through dealkylation and glucuronidation and is ex-
creted predominantly in bile. Buprenorphine pharmacokinetics
vary with route of administration. Whilst the sublingual (SL) and
intramuscular (IM) routes produce similar outcomes in terms of
pain-relief, when taken orally, buprenorphine undergoes extensive
pre-systemic elimination (Bullingham 1981; Bullingham 1983).
Oral bioavailability is therefore low (15%) due to extensive first-
passmetabolism in the gastrointestinalmucosa and liver.However,
it is longer-acting thanmorphine.Whilst buprenorphine is rapidly
absorbed via oral mucosa, absorption into the systemic circulation
is slow (tmax is 30 minutes to 3.5 hours after a single dose; one to
two hours with repeat dosing; Elkader 2005). However, it subse-
quently has a long duration of action (six to eight hours), which
suggests that SL buprenorphine may be not suited for the man-
agement of breakthrough pain. Poulain 2008 has demonstrated
the successful use of buprenorphine as a breakthrough analgesic
for patients on maintenance transdermal (TD) buprenorphine.
Buprenorphine activity as a partial agonist at the µ receptor means
it has agonist and antagonist activity. Its long duration of action
is thought to be due to an unusually slow dissociation constant
for the drug-receptor complex. Naloxone appears to be relatively
ineffective in reversing opioid effects from buprenorphine, de-
spite naloxone’s high affinity for the µ-opioid receptor (Gal 1989),
and this is due to buprenorphine’s even stronger receptor affin-
ity (Dahan 2010). In humans, a ceiling effect has been shown
with buprenorphine for respiratory depression but not for analge-
sia (Dahan 2005; Dahan 2006). Whilst buprenorphine has been
shown to slow intestinal transit, it possibly does this less than mor-
phine (Bach 1991; Robbie 1979); importantly, constipation as an
adverse effect may be less severe (Pace 2007). Buprenorphine also
exerts little or no pressure on pancreatic and biliary ducts, distin-
guishing it from morphine in this respect (Staritz 1986). Com-
pared with other opioids, buprenorphine causes little or no im-
munosuppression (Budd 2004; Sacerdote 2000; Sacerdote 2008).
As a drug, buprenorphine does not accumulate in renal failure and
is not removed by haemodialysis. This means that analgesia is un-
affected, making it potentially clinically useful in these situations
(Filitz 2006; Hand 1990).
Examples of buprenorphine patch preparations are three or seven
day TD formulations (5, 10, 20, 35, 52.5, 70 µg/hour). It is a
highly lipid-soluble drug, making it ideal for TD delivery.Within
patch formulations it is evenly distributed in a drug-in-adhesive
matrix and its release is governed by the physical attributes of
the matrix and proportional to the surface area of the patch. It is
also available as an injection (300 µg). Buprenorphine via either
the TD or injectable route is approved for managing moderate
to severe chronic pain. SL tablets and a SL film preparation are
also available in some countries and are combined with naloxone.
Currently these are used for the treatment of opioid addiction,
although some SL tablets (200 µg and 400 µg) without naloxone
are available for chronic moderate to severe pain. It should not
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be used for acute pain, e.g., when there is a need for rapid dose
titration for severe pain in cancer and palliative care settings.
Buprenorphine is most commonly prescribed as a TD formula-
tion for cancer patients. It is estimated to be 70 to 115 times
more potent than oral morphine (Likar 2008; Mercadante 2009;
Sittl 2005). In practical terms, the National Institute for Health
and Care Excellence (NICE) has suggested using caution when
calculating opioid equivalences for TD patches and that a TD
buprenorphine patch of 20 µg/hour equates to approximately 30
mg of oral morphine daily (NICE 2012). All opioid conversions
have to take into account inter-individual differences in such fac-
tors as pain perception and opioid receptor affinity. Research into
genetic, gender and immunological differences in how people re-
spond to opioids will form an ever-increasing part of pain man-
agement in the future.
Why it is important to do this review
Many patients with cancer experience moderate to severe pain
that requires treatment with strong analgesics. In 1986, theWHO
published the Method for Cancer Pain Relief (WHO analgesic
ladder), advocating a stepwise approach to analgesia for cancer
pain and revolutionising the use of oral opioids (WHO 1987).
It recommended that morphine be used as a first-line treatment
for moderate to severe cancer pain. Observational studies have
suggested that this approach results in pain control for 73% of
patients (Bennett 2008) with a mean reduction in pain intensity
of 65% (Ventafridda 1987).
Buprenorphine, oxycodone (Schmidt-Hansen 2015), fentanyl
(Hadley 2013), hydromorphone (Quigley 2002), methadone
(Nicholson 2007) and morphine (Wiffen 2013) are examples of
more commonly used opioids used for the relief of cancer pain
worldwide. However, Step III opioids are ineffective for treating
pain in all patients (Pergolizzi 2008) and are not well-tolerated
by all patients. However, buprenorphine does not accumulate in
renal impairment and is not removed by haemodynamics, making
it a practical analgesic in some situations where the use of other
strong opioids may be more problematic.
The aim of this Cochrane review is to assess whether buprenor-
phine is associated with superior, inferior or equal pain relief and
tolerability compared to other analgesic options for patients with
cancer pain.
O B J E C T I V E S
To assess the effectiveness and tolerability of buprenorphine for
pain in adults and children with cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), with parallel-group or cross-
over design, comparing buprenorphine (any formulation and any
route of administration) with placebo or an active drug (including
buprenorphine) for treating people with cancer background pain.
We did not examine studies on breakthrough pain.
Types of participants
Adults and children with cancer pain.
Types of interventions
• Buprenorphine (any dose, formulation and route of
administration) versus buprenorphine (any dose, formulation
and route of administration);
• Buprenorphine (any dose, formulation and route of
administration) versus other active drug (any dose, formulation
and route of administration);
• Buprenorphine (any dose, formulation and route of
administration) versus placebo.
Types of outcome measures
Primary outcomes
• Pain intensity and pain relief:
◦ Both outcomes had to be patient-reported and could
be reported in any transparent manner (e.g., by using numerical
or verbal rating scales);
◦ We did not consider these outcomes reported by
physicians, nurses or carers;
◦ If possible, we aimed to distinguish between
nociceptive and neuropathic pain. However, this was not
possible on the basis of the included trials.
In line with Wiffen 2013, we looked for outcomes that are equiv-
alent to ’no worse than mild pain’ (Moore 2013) operationalised
as either one of the following:
1. No or mild pain;
2. ≤ 3/10 on a numerical rating scale;
3. ≤ 30/100 mm on a visual analogue scale;
4. Positive ratings on patient measures of satisfaction (usually
very satisfied), or treatment success, or global impression of
change (very good, excellent).
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Secondary outcomes
Side effects or adverse events (e.g., constipation, nausea, vomiting,
drowsiness, confusion, respiratory depression), quality of life and
patient preference. We considered all of these outcomes as they
were reported in the included studies.
Search methods for identification of studies
We did not apply language, date or publication status (published
in full, published as abstract or unpublished) restrictions to the
search.
Electronic searches
We identified relevant trials by searching the following databases
on 20 January 2015:
1. Cochrane Central Register of Controlled Trials,
(CENTRAL; Issue 12 of 12, 2014, the Cochrane Library);
2. MEDLINE (OVID; 1948 to 20 January 2015);
3. EMBASE (OVID; 1980 to 20 January 2015);
4. Web of Science (ISI) (SCI-EXPANDED & CPCI-S) to 20
January 2015;
5. BIOSIS (ISI) (1969 to 20 January 2015).
We have listed the electronic search strategies in Appendix 1.
Searching other resources
We checked the bibliographic references of identified stud-
ies, as well as relevant studies and systematic reviews in
order to find additional trials not identified by the elec-
tronic searches. We also searched ClinicalTrials.gov (http://
clinicaltrials.gov/), the metaRegister of Controlled Trials (mRCT)
(http://www.controlled-trials.com/mrct/), the WHO Interna-
tional Clinical Trials Registry Platform (ICTRP) search por-
tal (http://apps.who.int/trialsearch/) and the Proceedings of the
Congress of the European Federation of International Association
for the Study of Pain (IASP; via European Journal of Pain Sup-
plements) up to 16 February 2015 as complementary sources for
related studies. We contacted authors of the included studies to
ask if they knew of any other relevant studies.
Data collection and analysis
Selection of studies
Two review authors (MSH, JH) assessed the titles and abstracts
of all the studies identified by the search for potential inclusion.
We independently considered the full records of all potentially
relevant studies for inclusion by applying the selection criteria
outlined in the Criteria for considering studies for this review
section.We resolved potential disagreements by discussion.Wedid
not restrict the inclusion criteria by date, language or publication
status (published in full, published as abstract, unpublished).
Data extraction and management
Using a standardised data extraction form, two review authors
extracted data pertaining to study design, participant detail (in-
cluding age, cancer characteristics, previous analgesic medication
and setting), interventions (including details about titration) and
outcomes. We resolved potential disagreements by discussion. In
studies in which only a subgroup of the participants met the in-
clusion criteria for this review, we only extracted the data on this
subgroup provided randomisation was not broken.
Assessment of risk of bias in included studies
Two review authors independently assessed the methodological
quality of each included study by using the Cochrane Collabora-
tion’s ’Risk of bias’ assessment tool (Higgins 2011). For each study
we assessed the risk of bias for the following domains:
• Selection bias (study level: random sequence generation,
allocation concealment);
• Performance bias (outcome level: blinding of patients,
blinding of treating personnel);
• Detection bias (outcome level: blinding of outcome
assessment);
• Attrition bias (outcome level: incomplete outcome data);
• Reporting bias (study level: selective reporting).
In addition, we included an item that assesses the adequacy of
titration. Each of the items from the above domains required a ’low
risk’, ’high risk’ or ’unclear risk’ response.We also documented the
reasons for each response in accordance with Higgins 2011.We re-
solved potential disagreements through discussion. In addition to
this strategy for ’Risk of bias’ assessment in the individual studies,
we considered the impact that study size may have on the validity
of the results. We assessed the overall quality of the evidence for
each outcome using the GRADE approach (Guyatt 2008).
Measures of treatment effect
For continuous outcomes we extracted the means and standard
deviations (SDs), where possible, with the intention of using these
to estimate the mean difference (MD) between the treatments
along with the 95% confidence interval (CI), if the outcome were
measured on the same scale in the studies. Where the outcome was
measured on different scales, we intended to report the standard-
ised mean difference (SMD) with 95%CIs instead when perform-
ing meta-analyses. However, this was not feasible. For dichoto-
mous outcomes we extracted event rates but did not, as planned,
calculate risk ratios (RRs) and number needed to treat for an ad-
ditional beneficial outcome (NNTB)/number needed to treat for
an additional harmful outcome (NNTH), again because no meta-
analyses were performed.
11Buprenorphine for treating cancer pain (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Unit of analysis issues
Our plan to deal with any unit-of-analysis issues was to consider
the patient the unit of analysis. However, if the data reported in
any included cross-over trials could not be otherwise incorporated
into the analyses (seeDealing withmissing data), wewould include
them as if the design had been parallel group. Higgins 2011 points
out that this approach, while giving rise to unit-of analysis error, is
nevertheless conservative as it results in an under-weighting of the
data. Moreover, if we included cross-over trial data in this manner
we would perform sensitivity analyses assessing the impact of this
strategy. However, as we did not perform any meta-analyses, this
strategy was not used.
Dealing with missing data
In cases where data were missing, we contacted the trial authors to
request missing data. However, we received no replies.We planned
to limit missing data imputation to the imputation of missing SDs
if enough information was available from the studies to calculate
the SD according to themethods outlined byHiggins 2011. How-
ever no missing data were imputed in this manner as no meta-
analyses were performed. We have recorded the drop-out/missing
data rates in the ’Risk of bias’ tables under the items on attrition
bias, and we addressed the potential effect of the missing data on
the results, not in sensitivity analyses as originally planned, but in
the Discussion section. Although we aimed to perform intention-
to-treat (ITT) analyses, we were unable to do so in all cases as we
were unable to perform meta-analyses.
Assessment of heterogeneity
We planned to assess heterogeneity by using the I2 statistic, with I
2 values > 50% representing substantial heterogeneity in line with
Higgins 2011.We aimed to assess potential sources of heterogene-
ity through subgroup analyses as outlined in Subgroup analysis
and investigation of heterogeneity. However as we were unable to
undertake any meta-analyses, we did not perform these subgroup
analyses.
Assessment of reporting biases
In addition to implementing the comprehensive search strategy
outlined in the sectionSearchmethods for identification of studies,
the risk of outcome reporting bias is included in the ’Risk of bias’
summary figures (Figure 1; Figure 2) that we constructed for each
study and each type of assessed bias.
Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
12Buprenorphine for treating cancer pain (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Data synthesis
We planned to enter the data extracted from the included stud-
ies into the Cochrane Collaboration’s statistical software, Review
Manager 2014, in order to use this for data synthesis. We planned
to analyse continuous outcomes using the generic inverse variance
method, and dichotomous outcomes using the Mantel-Haenszel
method in accordance with Higgins 2011. If the I2 statistic value
was > 50% we planned to use a random-effects model and con-
sider not reporting a summary estimate of the data (depending
on the subgroup analyses; see also the section Subgroup analysis
and investigation of heterogeneity). Otherwise we would use a
fixed-effect model for the meta-analyses. However, as it was not
feasible to meta-analyse the data from the included studies, we
summarised the data narratively and in tables. We have also, as
planned, summarised the results for all the listed outcomes in a
’Summary of findings’ table.
Subgroup analysis and investigation of heterogeneity
Different aspects of the trials are likely to contribute heterogene-
ity to the proposed main analyses. If there were sufficient data,
we planned to perform subgroup analyses based on doses, titra-
tion, routes of administration (e.g., SL, TD), length of the trials
and populations (e.g., opioid-naive patients, solid/haematological
cancer type, adults/children, co-morbidities). However, there were
insufficient data to perform such analyses.
Sensitivity analysis
If sufficient data were available, we aimed:
1. To examine the robustness of the meta-analyses by
conducting sensitivity analyses using different components of the
’Risk of bias’ assessment, particularly those relating to whether
allocation concealment and blinding were adequate;
2. To conduct further sensitivity analyses to examine the
impact of missing data on the results if a large proportion of the
studies were at an ’unknown’ or ’high risk’ of attrition bias; and
3. To perform sensitivity analyses examining whether
publication status and trial size influenced the results.
However, we did not perform any sensitivity analyses because there
were insufficient data.
R E S U L T S
Description of studies
Results of the search
The search identified 475 unique records of which we excluded
419 based on the title/abstract. We retrieved 56 records for full-
text evaluation. Of the 56 records, we included 19 studies pub-
lished in 23 articles, while we excluded 33 because theywere not in
PICO (i.e., an RCT conducted in the target population examining
the target comparisons as measured by the target outcomes; N =
14), withdrawn (N = 1), narrative reviews (N = 7) or duplicates
(N = 2) (see Figure 3). In addition to the 19 included studies, we
identified four ongoing studies and five potentially relevant stud-
ies . We await further information, including study completion
and publication, of the latter before we can ascertain their rele-
vance to the current review and classify them accordingly. See also
Characteristics of ongoing studies and Characteristics of studies
awaiting classification, respectively.
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Figure 3. Study flow diagram.
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Included studies
The 19 included studies were published between 1979 and 2012
and enrolled/randomised a total of 1421 patients (study range 10
to 189) with 1304 (study range 10 to 188) of these analysed for
efficacy and 1216 (study range 12 to 189) for safety (Rigolot 1979;
Wang 2012 did not report this outcome). The reported mean ages
of the patient populations in the studies ranged from 49.1 years
to 67.16 years. Four studies were crossover trials (Bono 1997; De
Conno 1987; Kjaer 1982; Rigolot 1979) and the remainder were
parallel-group trials, with six studies conducted in Italy (Bono
1997; Brema 1996; De Conno 1987; Dini 1986; Pace 2007;
Pasqualucci 1987), two in Japan (Dan 1989; Noda 1989) and in
the following countries: Denmark (Kjaer 1982); Germany (Bauer
1985); Austria, Germany and Hungary (Böhme 2003); Mexico (
LimónCano 1994); Austria, Belgium,Croatia, France, Poland and
the Netherlands (Poulain 2008); France (Rigolot 1979); Egypt (
Sarhan 2009); Austria, Germany and theNetherlands (Sittl 2003);
Germany and Poland (Sorge 2004); China (Wang 2012); and
India (Yajnik 1992). The treatment groups in the included studies
were either comparable at baseline (Dan 1989; Kjaer 1982; Pace
2007; Poulain 2008;Wang 2012; Yajnik 1992), not comparable at
baseline (Böhme 2003 (age); Sittl 2003 (age); Sorge 2004 (disease
stage)), or it was unclear (e.g., due to lack of reporting of baseline
characteristics whether they differed; Bauer 1985 (age); Bono
1997 (baseline pain); Brema 1996 (gender); DeConno 1987;Dini
1986; Limón Cano 1994 (age, gender); Noda 1989 (cancer type
and stage); Pasqualucci 1987; Rigolot 1979; Sarhan 2009). Three
of the studies included patients with pain of a both malignant and
non-malignant origin (Böhme 2003; Sittl 2003; Sorge 2004).One
of these studies presented some of the results split by pain origin
(32.8% of the patients had cancer pain; Sorge 2004). The other
two studies did not present the results separately for the patients
with cancer pain, but they were still included as the percentage of
patients with malignant pain were above 50 in both studies (55%
in Böhme 2003; and 77.1% in Sittl 2003). Trial length ranged
from single dose treatment to six months, and the studies reported
the following comparisons:
• SL buprenorphine versus subdermal (SD) buprenorphine
injection (Limón Cano 1994);
• SL buprenorphine versus oral tilidin + naloxone (Bauer
1985);
• SL buprenorphine versus oral tramadol (Bono 1997; Brema
1996);
• SL buprenorphine versus SL buprenorphine + oral
phenytoin versus oral phenytoin (Yajnik 1992);
• SL buprenorphine versus oral pentazocine (De Conno
1987);
• Buprenorphine tablets/fluid versus pentazocine tablets/fluid
(Dini 1986);
• TD buprenorphine versus placebo (Böhme 2003; Poulain
2008; Sittl 2003; Sorge 2004);
• TD buprenorphine versus controlled-release morphine
(Pace 2007);
• TD buprenorphine versus TD fentanyl (Sarhan 2009);
• IM buprenorphine injection versus buprenorphine
suppository (Dan 1989);
• IM buprenorphine versus IM morphine (Kjaer 1982;
Rigolot 1979);
• IM buprenorphine + SC buprenorphine versus SC
buprenorphine versus placebo + SC buprenorphine (Noda
1989);
• Epidural buprenorphine versus epidural morphine
(Pasqualucci 1987);
• Intravenous buprenorphine versus intravenous morphine
(Wang 2012).
See alsoCharacteristics of included studies for further details about
the studies.
Excluded studies
We excluded 33 studies because they were not in PICO (i.e., an
RCT conducted in the target population examining the target
comparisons as measured by the target outcomes; N = 14), with-
drawn (N=1), narrative reviews (N =7) or duplicates (N =2).One
of the studies identified in the search compared buprenorphine in
combination with diclofenac against buprenorphine alone (Corli
1988). We excluded this study as it would not answer our primary
question which is concerned with the effectiveness of buprenor-
phine for cancer pain. See also Characteristics of excluded studies.
Risk of bias in included studies
In this section we have described the risk of bias for the included
studies. See also Figure 1 and Figure 2 for summaries of the risk
of bias judgements.
Allocation
We considered generation of the randomisation sequence to be
at low risk of bias in only two included trials (Pace 2007; Sorge
2004). A third study was considered to be at high risk of selection
bias because it included only 120 patients that were allocated to
one of four treatment groups with stratification for several factors.
With each stratification factor it became increasingly conceivable
that the group allocation ceased to be truly random or, indeed,
concealed given the relatively high number of treatment groups to
the relatively lownumber of patients (Wang 2012). The remaining
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included studies did not report enough information to enable us
to assess the risk of selection bias. Therefore we considered them
at unclear risk of selection bias.
Blinding
Lack of reporting was also an issue when assigning risk of bias
estimates to the items assessing performance and detection bias,
i.e., blinding. Very few trials reported directly who was blinded, so
in most cases we inferred on the basis of supplementary informa-
tion whether we were reasonably certain that blinding had been
adequately executed for a given individual (i.e., patient, treating
personnel or the outcome assessors, or both, where not the pa-
tients themselves). On this basis, we considered the risk of per-
formance bias to be low for the primary outcome of pain and for
the secondary outcome of adverse events in three studies (Dan
1989; Kjaer 1982; Poulain 2008), high in one study described as
open label (Pace 2007) and unclear in the remaining 13 studies
that reported this outcome. We considered eight studies at low
risk of detection bias for pain (which according to our criteria
had to be patient-assessed) either because it was clearly stated that
the patient was blinded (Dan 1989; Kjaer 1982; Poulain 2008;
Rigolot 1979 (although in this study it is not clear whether pain
is patient-assessed)) or because the study was described as double-
blind without stating who was blinded (i.e., patient, treating per-
sonnel or outcome assessor) and we considered it sufficiently likely
that at least the patient was blinded (Böhme 2003; Pasqualucci
1987; Sittl 2003; Sorge 2004; see also Characteristics of included
studies). Apart from Pace 2007, judged at high risk due to being
open label, we judged the remaining studies to be at unclear risk
of detection bias for the outcome of pain. In the case of adverse
events, it was often unclear who reported/assessed this outcome.
Therefore we felt unable to assume with sufficient confidence that
it had be assessed in a blinded manner (unlike with pain as de-
scribed above), unless it had been clearly stated.We considered the
risk of detection bias for adverse events to below in four studies
that all clearly stated that the outcome assessor was blinded (Dan
1989; Kjaer 1982; Poulain 2008; Sittl 2003), high in one open
label study (Pace 2007) and unclear in the remaining 12 studies
reporting this outcome.
Incomplete outcome data
Overall the data from 91.8% of the total number of enrolled/
randomised patients were analysed for pain. We judged the risk
of attrition bias as low in most included studies (Bauer 1985;
Böhme 2003; Brema 1996; Kjaer 1982; Limón Cano 1994; Pace
2007; Pasqualucci 1987; Poulain 2008; Rigolot 1979; Sittl 2003;
Sorge 2004; Yajnik 1992), with three studies considered at high
risk (Bono 1997; Dan 1989; De Conno 1987) and four studies
considered at unclear risk (Dini 1986; Noda 1989; Sarhan 2009;
Wang 2012) of attrition bias, respectively. For adverse events, we
analysed the data from 85.6% of the total number of enrolled/
randomised patients, and we considered the risk of attrition bias
to be low in 12 included studies (Böhme 2003; Bono 1997;
Brema 1996; Dan 1989; Kjaer 1982; Limón Cano 1994; Pace
2007; Pasqualucci 1987; Poulain 2008; Sittl 2003; Sorge 2004;
Yajnik 1992), high in one study (De Conno 1987) and unclear in
the remaining four studies (Bauer 1985; Dini 1986; Noda 1989;
Sarhan 2009) that reported this outcome. Rigolot 1979 andWang
2012 did not report adverse events.
Selective reporting
We considered 13 included studies to be at low risk of reporting
bias, with Rigolot 1979 and Wang 2012 considered at high risk
of reporting bias as neither reported adverse events. We judged
the remaining four studies (Bauer 1985; De Conno 1987; Limón
Cano 1994; Sarhan 2009) at unclear risk of reporting bias due to
under-reporting from being available either only in abstract form
or in a foreign language.
Other potential sources of bias
Patients appeared to be adequately titrated in only four studies
(Böhme 2003; Poulain 2008; Sittl 2003; Sorge 2004), and in-
adequately or not titrated in a further seven studies (De Conno
1987; Kjaer 1982; Limón Cano 1994; Noda 1989; Pace 2007;
Pasqualucci 1987; Rigolot 1979). Titration schedule or adequacy,
or both, was unclear in the remaining eight studies.
Apart from five studies which reported to have received commer-
cial funding (Böhme 2003; Kjaer 1982; Poulain 2008; Sittl 2003;
Sorge 2004), it was unclear whether the remaining studies received
such funding.
Data were available for both cross-over phases for three of the four
crossover trials included (De Conno 1987; Kjaer 1982; Rigolot
1979). We considered these trials to be at low risk of bias, whereas
we judged the final trial (Bono 1997) to be at high risk of bias
because the pain intensity data did not appear to be inferentially
analysed collapsed over phases for any of the seven (per phase)
study days, apart from for the first four hours of treatment.
Nine included studies appeared to conduct the analyses according
to the ITTprinciple (Bauer 1985; Brema1996;Kjaer1982; Limón
Cano 1994; Pace 2007; Pasqualucci 1987; Poulain 2008; Sittl
2003; Sorge 2004), although this was often not clearly stated. In
the remaining studies it was either unclear if ITT analyses were
performed (Böhme 2003; Dini 1986; Noda 1989; Rigolot 1979;
Sarhan 2009; Wang 2012; Yajnik 1992) or they were clearly not
performed (Bono 1997; Dan 1989; De Conno 1987).
With the exception of four studies (Böhme 2003; Pace 2007;
Sittl 2003; Sorge 2004) which we judged at low risk of ’other
bias’, for most included studies we were unable to evaluate with
sufficient confidence whether they were subject to other kinds of
bias due to the very limited reporting that this body of evidence
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generally suffered from (Bauer 1985; Bono 1997; Brema 1996;
Dan 1989; DeConno 1987; Dini 1986; Kjaer 1982; Limón Cano
1994;Noda 1989; Pasqualucci 1987; Poulain 2008; Rigolot 1979;
Sarhan 2009; Wang 2012; Yajnik 1992).
Effects of interventions
See: Summary of findings for the main comparison
SL buprenorphine versus SD buprenorphine
LimónCano 1994 conducted a placebo-controlled, parallel-group
study of (it seems) 24-hour duration comparing SL buprenorphine
(N = 10) to SD buprenorphine (N = 7) administered every four
to eight hours on a patient-need basis. Both treatments resulted
in a 50% reduction in pain intensity, with faster onset of pain
relief observed in the SL group (63 ± 22.1 min) compared to
the subdermic group (94.3 ± 22.7 min). The mean duration of
analgesia was similar between the SL (7.4 ± 1.2 hours) and the SD
(6.8 ± 1.2 hours; P > 0.2) groups, and no significant differences
in adverse event rates were reported (see also Table 1).
SL buprenorphine versus oral tilidine-HCI +
naloxone-HCI
Bauer 1985 conducted a parallel-group, 28-day study with 20
women in each group comparing SL buprenorphine to oral ti-
lidine with naloxone. This study found that the pain intensity
ratings, which were comparable at baseline (7.16 for buprenor-
phine versus 7.11 for tilidine + naloxone), were significantly lower
for the patients who received buprenorphine on days 1 (4.31 for
buprenorphine versus 4.97 for tilidine + naloxone), 7 (3.43 for
buprenorphine versus 4.58 for tilidine + naloxone), 14 (3.83 for
buprenorphine versus 4.54 for tilidine + naloxone) and 21 (4.06
for buprenorphine versus 4.56 for tilidine + naloxone), but not on
day 28, where it was only numerically lower (4.07 for buprenor-
phine versus 4.42 for tilidine + naloxone). The mean number
of drug administrations necessary to achieve satisfactory analge-
sia was 39 (range = 26 to 52) in the buprenorphine group and
60 (range = 36 to 104) in the tilidine + naloxone group over
the 28-day study period (P < 0.05). The mean interval between
drug administrations was 17.6 (range = 12.8 to 25.5) hours in the
buprenorphine group and 11.85 (range = 6.4 to 17.7) hours in the
tilidine + naloxone group (P < 0.05). The trial authors reported
that there did not seem to be any detectable increase in analgesic
requirements due to tachyphylaxis for any of the drugs, and all the
patients in both treatment groups described the analgesic effective-
ness as satisfactory. Treatment-related side effects such as nausea,
vomiting and fatigue, and constipation occurred with the same
frequency in both groups, and led to no cases of discontinuation
of treatment (see also Table 1).
SL buprenorphine versus oral tramadol
Bono 1997 undertook a cross-over study with two phases, each
lasting 7 days, comparing SL buprenorphine to oral tramadol in
60 patients. The pain intensity data did not appear to be inferen-
tially analysed where it was collapsed over phases for (any of ) the
study days, apart from for the first four hours of treatment, where
no differences were observed between the treatments. Other anal-
yses that appeared to include all patients collapsed across phases
showed:
1. Ratings of pain intensity relative to the pain intensity
experienced the previous day did not differ significantly between
the treatment groups;
2. Tramadol treatment was associated with significantly better
quality of sleep than buprenorphine on days 6 and 7, but not on
days one to five where no differences were observed;
3. Significantly better patient ratings of tolerability (mean =
80.1, SEM = 2.3) compared to buprenorphine (mean = 41.8,
SEM = 4.1);
4. The number of patients with side effects was also lower
during tramadol (9/60 patients) than buprenorphine treatment
(34/60 patients; see also Table 1).
In a parallel-group trial planned to last up to six months, Brema
1996 compared SL buprenorphine (N = 63) to slow-release tra-
madol (N = 68). The mean duration of treatment was 50.9 days
in the buprenorphine group and 57.7 days in the tramadol group.
One patient in the buprenorphine group and four patients in the
tramadol group completed the six months of treatment. At base-
line, 92% buprenorphine and 98.4% tramadol patients reported
’strong-to-unbearable’ pain, which reduced to 66.7% and 48.4%
respectively at seven days and to 54.5% and 43.1%, respectively, at
day 14. These percentages differed statistically significantly at day
7, but this significance had disappeared by day 14, and may have
been a result of quicker titration with tramadol than buprenor-
phine in the early stage of the study. No significant differences
in the percentage of patients reporting good deep sleep were ob-
served between the buprenorphine and tramadol patients at base-
line (buprenorphine 32.7%, tramadol 37.2%), day 7 (buprenor-
phine 40%, tramadol 51.1%) or day 14 (buprenorphine 43.9%,
tramadol 50%). After two weeks of treatment the overall treat-
ment efficacy was rated as higher in the tramadol (mean 100-mm
VAS = 62.3, SD = 26.7) than in the buprenorphine (mean 100-
mm VAS = 57.2, SD = 25.6) group although not significantly so.
This was also the case at the end of treatment and at this stage
the difference may have become significant although this cannot
be ascertained based on the reported results (tramadol: mean 100-
mm VAS = 60.9, SD = 27.8; buprenorphine: mean 100-mm VAS
= 47.4, SD = 26; P ≤ 0.05). After two weeks of treatment the
overall treatment acceptability was rated as significantly higher in
the tramadol (mean 100-mm VAS = 70.7, SD = 19.8) than in the
buprenorphine (mean 100-mm VAS = 58.9, SD = 24.5) group.
This was also the case at the end of treatment, although it is appar-
ently only marginally significantly higher at this stage (tramadol:
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mean 100-mm VAS = 69.2, SD = 19.1; buprenorphine: mean
100-mm VAS = 58.3, SD = 22.9; P ≤ 0.05). The trial authors
also reported that in the tramadol group 71.4% of the patients
reported moderate/no pain in the first month and 80% did so
in the second month, with the corresponding percentages for the
buprenorphine group at 45.4% after one month and 65.2% after
two months, but reported no inferential statistics. We have listed
the adverse events in Table 1.
SL buprenorphine versus SL buprenorphine + oral
phenytoin versus oral phenytoin
Yajnik 1992 conducted a parallel-group trial of one month du-
ration comparing treatment with SL buprenorphine, with SL
buprenorphine + oral phenytoin and with phenytoin in three
groups of 25 patients, and found no significant difference in pain
relief rates after one month between the buprenorphine (good: 15/
25; moderate: 6/25; poor: 4/25; none: 0/25), the buprenorphine +
phenytoin (good: 18/25; moderate: 4/25; poor: 2/25; none: 1/25)
and phenytoin (good: 4/25; moderate: 14/25; poor: 5/25; none:
2/25) groups. The groups did not differ significantly in incidence
of adverse events (see Table 1).
SL buprenorphine versus oral pentazocine
De Conno 1987 compared SL buprenorphine with oral penta-
zocine in a cross-over study lasting 14 days (seven days per phase)
in 120patients, ofwhom29didnot complete the study.This study
found that buprenorphine was associated with significantly better
pain relief compared to pentazocine, reducing the mean daily pain
intensity 10 to 25 points more than pentazocine. Patients also
slept statistically significantly more (on average one hour) during
treatment with buprenorphine compared to treatment with pen-
tazocine. Also, they spent 10 to 30 minutes longer a day standing
during the buprenorphine treatment phase than pentazocine treat-
ment, although it is unclear whether this difference is statistically
significant. Buprenorphine was associated with significantly more
drowsiness, whereas pentazocine was associated with significantly
more dizziness and stomach pain. Otherwise the side effects pro-
files did not differ significantly between the treatments (see also
Table 1). Of the 29 patients who did not complete the study, more
patients stopped study treatment during the pentazocine phase (N
= 16) than during the buprenorphine phase (N = 3; P = 0.03).
Buprenorphine tablets/fluid versus pentazocine
tablets/fluid
Dini 1986 conducted a parallel-group study with four experimen-
tal groups (buprenorphine SL tablets and vials, pentazocine tablets
and vials) of seven days duration with a total of 42 patients, of
whom two (one each treated with buprenorphine and pentazocine
tablets) did not complete the course of therapy due to excessive
nausea and vomiting. Dini 1986 reported that the final daily av-
erage pain intensity was significantly lower after treatment with
buprenorphine tablets (mean = 58, SE = 19) compared to pen-
tazocine tablets (mean = 118, SE = 23). This pattern of results
was also observed when comparing treatment with buprenorphine
vials/fluid (mean = 38, SE = 9) and pentazocine vials/fluid (mean
= 115, SE = 15). Treatment with buprenorphine vials/fluid was as-
sociated with a longer time spent asleep (mean = 8 hours, SE = 0.6
hours) relative to pentazocine vials/fluid (mean = 6.5 hours, SE =
0.4 hours). However, this effect was not observed after treatment
with the tablet forms of buprenorphine (mean = 7.2 hours, SE
= 0.6 hours) and pentazocine (mean = 7 hours, SE = 0.6 hours),
which did not differ statistically significantly. No differences were
observed either in time spent awake in the supine position between
treatment with buprenorphine vials/fluid (mean = 15 hours, SE =
1.8 hours) and pentazocine vials/fluid (mean = 17 hours, SE = 2.1
hours) or between treatment with buprenorphine tablets (mean =
13.5 hours, SE = 2.2 hours) and pentazocine tablets (mean = 11.9
hours, SE = 2.1 hours). No differences were observed between the
treatment groups in time spent sitting or standing either. The trial
authors did not report any formal statistical comparisons for the
patient ratings of treatment effectiveness and tolerability, which
are therefore only reported descriptively: patients rated effective-
ness of treatment after treatment with buprenorphine tablets as
excellent (three patients), good (six patients) and fair (one patient);
as good (one patient), fair (one patient), poor (six patients) and
nothing (two patients) after treatment with pentazocine tablets; as
excellent (three patients), good (seven patients) and fair (one pa-
tient) after treatment with buprenorphine vials/fluid; and as good
(two patients), fair (five patients) and poor (three patients) after
treatment with pentazocine vials/fluid. Patients rated tolerability
of treatment after treatment with buprenorphine tablets as excel-
lent (9 patients), good (one patient) and poor (one patient); as
good (two patients), fair (four patients), and poor (four patients)
after treatmentwith pentazocine tablets; as excellent (five patients),
good (five patients) and fair (one patient) after treatment with
buprenorphine vials/fluid; and as excellent (one patient), good (six
patients), fair (one patient) and poor (two patients) after treatment
with pentazocine vials/fluid. We have reported adverse events in
Table 1.
TD buprenorphine versus placebo
Böhme 2003 is a six day, four-arm, parallel-group trial that in-
cluded patients with pain from both malignant (55%) and non-
malignant (45%) origin and compared placebo (N = 37) to TD
buprenorphine at three different doses, 35 µg/h (N = 35), 52.5
µg/h (N = 41) and 70 µg/h (N = 38). Böhme 2003 found that
the number of patients who responded to treatment (i.e., patients
who obtained at least satisfactory pain relief at all determination
points (excluding the final examination) and who took a mean of
0.2 mg/day or less of SL buprenorphine on days seven to 12) and
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the mean daily doses of rescue medication (SL buprenorphine)
did not differ significantly between the four groups. No significant
differences in rates of adverse events were observed between the
groups (see Table 2).
In a study similar to Böhme 2003, Sittl 2003 conducted a 15-
day long parallel group trial in 157 patients with both malignant
(77.1%) and non-malignant (22.9%) pain comparing placebo (N
= 38) to TD buprenorphine at three different doses, 35 µg/h
(N = 41), 52.5 µg/h (N = 41) and 70 µg/h (N = 37). Sittl
2003 found that the two lower doses of buprenorphine (35 µg/
h: 36.6%; 52.5 µg/h: 47.5%; 70 µg/h: 33.3%) were found to
have a significantly higher percentage of responders (i.e., patients
requiring no more than one SL tablet of buprenorphine (rescue
medication) per day from day 2 until the end of the study and
who recorded at least satisfactory pain relief at each application of
a new patch) than placebo (16.2%). The percentage reduction in
mean daily dose of rescue medication relative to pre-study was also
significantly larger in all the buprenorphine treatment groups (35
µg/h: -56.9%; 52.5 µg/h: -61.6%; 70 µg/h: -51.6%) compared
to placebo (-8%), but did not differ significantly from each other.
The mean overall ratings of pain relief were also higher in the
buprenorphine groups (35 µg/h: 2.3/4; 52.5 µg/h: 2.4/4; 70 µg/
h: 2.5/4) than in the placebo group (1.9/4), but it is unclear if they
are significantly so.Moreover, 8/37 (placebo), 9/41 (35µg/h), 15/
40 (52.5 µg/h) and 8/37 (70 µg/h) patients, respectively, rated
their pain relief as satisfactory over the course of the study, with a
further 12/37 (placebo), 19/41 (35 µg/h), 16/40 (52.5 µg/h) and
16/36 (70 µg/h) patients, respectively, rating their pain relief as
good or complete. The mean ratings of daily pain intensity were
’moderate-very severe’ in 60% (placebo), 52% (35 µg/h), 40%
(52.5 µg/h) and 37% (70 µg/h) patients, respectively; ’mild’ in
31% (placebo), 29% (35 µg/h), 42% (52.5 µg/h) and 43% (70
µg/h) patients, respectively, and ’none’ in 9% (placebo), 19% (35
µg/h), 18% (52.5µg/h) and 20% (70µg/h) patients, respectively
(no inferential statistical analyses reported). The incidence of none
of the reported adverse events differed significantly between the
four treatment groups (see Table 2 for the reported adverse events).
Another parallel-group study of two weeks duration, Poulain
2008, compared placebo (N = 95) to 70 µg/h TD buprenorphine
(N =94) and found that the proportion of responders (i.e., patients
with a mean pain intensity < five during the last six days of the
maintenance phase and a mean daily SL buprenorphine (rescue
medication) intake≤ 2 tablets over the entire maintenance phase)
was significantly higher in the buprenorphine group (70/94) com-
pared to the placebo group (47/94). The baseline-corrected pain
intensity and rescue medication tablet intake at the end of the
two-week maintenance phase were also significantly lower in the
buprenorphine group (pain intensity: least square mean = 0.23,
SE = 0.15; rescue medication tablet intake: least square mean = -
0.76, SE = 0.14) than in the placebo group (pain intensity: least
square mean = 1.14, SE = 0.17; rescue medication tablet intake:
least square mean = -0.23, SE = 0.15). Also, 51/94 buprenorphine
patients and 39/94 placebo patients rated their global satisfaction
with treatment as ’excellent’ or ’very good’ with a further 32 and
33 patients, respectively, giving ’good’ or ’fair’ ratings and nine
buprenorphine patients and 19 placebo patients giving a rating of
’poor’ (see Table 2 for the reported adverse events).
Sorge 2004 is a nine-day, parallel-group trial that included patients
with pain of both malignant (N = 45) and non-malignant origin
(N =92), but presented some of the results by pain origin (of which
only those relating to malignant pain are included here). Sorge
2004 compared placebo (N = 19) to 35 µg/h TD buprenorphine
(N = 26). This study found that the mean (SD) daily requirement
for SL buprenorphine (rescue medication) tablets was 1.2 (0.3) in
the run-in phase and 0.4 (0.5) in the double-blind phase for the
buprenorphine group and 1 (0.2) and 0.6 (0.3), respectively, in
the placebo group. No inferential statistics and no further efficacy
results were reported separately for the patients with cancer pain
(see Table 2 for the reported adverse events).
TD buprenorphine versus controlled-release
morphine
Pace 2007 compared TD buprenorphine to controlled-release
morphine in an eight-week long parallel-group trial with 26 pa-
tients in each arm. Pace 2007 found that buprenorphine was as-
sociated with significantly lower pain scores from week 2 of treat-
ment and with less interference with sleep from week 1 of treat-
ment as well as with higher quality of life in terms of ’physical pain’,
’mental health’ and ’vitality’, with significant differences between
the groups on the quality of life items of ’physical activity’, ’limited
activity due to physical problems’, ’social activity’, ’limited activity
due to emotional problems’ and ’problems of general health’. The
study also showed that buprenorphine treatment was associated
with lower anger/aversion, fatigue/inertia and total mood disor-
der scores and significantly higher strength/activity scores than
morphine. Twenty-five of the 26 buprenorphine patients and 19
of the 26 morphine patients indicated that their global impres-
sion of change was ’moderately better’ or ’considerable improve-
ment’. Eleven buprenorphine patients and 16 morphine patients
needed supplemental analgesia with tramadol, with seven and nine
buprenorphine and morphine patients, respectively, needing 100
mg tramadol and the remainder needing 200 mg tramadol. The
morphine patients had significantly higher rates of vertigo, consti-
pation and nausea, but no differences were observed between the
groups in rates of drowsiness, headache and confusion (see Table
2).
TD buprenorphine versus TD fentanyl
In a parallel-group study lasting six weeks, Sarhan 2009 compared
escalating doses of TD buprenorphine (N = 16) and TD fentanyl
(N = 16). Sarhan 2009 reported that the only significant differ-
ences that this study revealed were that buprenorphine was asso-
ciated with significantly higher rates of drowsiness and local skin
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complications compared to fentanyl. The mean pain scores, mean
number of each category patch dose, treatment satisfaction, mean
daily dose of diclofenac sodium, mean cost of the treatment and
other side effects and complications did not differ significantly
between the groups during the six weeks (see Table 2).
IM buprenorphine versus buprenorphine suppository
Dan 1989 is a parallel-group study consisting of two consecu-
tive treatments six to eight hours apart of the study drugs. Dan
1989 found that after the first administration of buprenorphine,
the number of people who rated their pain intensity as “none” or
“little” changed from 0 out of 34 patients at baseline to 23, 24
and 19 patients at 2, 4 and 6 hours in the rectal buprenorphine
group and to 27, 30, and 28 (out of 35) patients, respectively,
in the IM buprenorphine group. Before the second administra-
tion of the study drugs, 18 and 19 patients in the rectal and IM
buprenorphine groups, respectively, described their pain intensity
as “none” or “little”. This changed to 26, 26 and 24 (out of 33)
patients in the rectal buprenorphine group and to 22, 22, 22 (out
of 28) patients in the IM buprenorphine group at 2, 4 and 6 hours
after the second drug administration. Pain intensity ratings did
not differ significantly between the groups at any point. Only one
patient rated their pain intensity as “severe” after either the first
(at two and six hours, and just before the second administration)
or after the second (six hours) study drug administration (of IM
buprenorphine). The overall ratings of pain relief at study end
showed that most patients rated the drugs as “effective” (32 out of
34 rectal buprenorphine patients and 31 out of 34 IM buprenor-
phine patients) with the remaining patients rating the drugs as
“minor response” and no patients giving a rating of “ineffective”
with no statistically significant differences between the groups ob-
served. While the severity of drowsiness, feeling heavy-headed,
sweating, thirst, urinary retention, euphoria and fatigue did not
differ significantly between the groups, Dan 1989 found that the
average severity of dizziness, nausea, vomiting, and adverse events
as a total were all significantly higher in the IM group relatively to
the suppository group (see Table 3).
IM buprenorphine versus IM morphine
In a crossover study lasting a total of eight days Rigolot 1979 com-
pared IM buprenorphine to IM morphine in 10 patients. Rigolot
1979 reported that, when analysed separately, both morphine and
buprenorphine are associated with significantly lower pain inten-
sities at hours one to five compared to baseline. When compared
directly, no significant differences were observed between the two
treatments in analgesic efficacy at any of the measured times.
Rigolot 1979 did not report adverse events.
Kjaer 1982 conducted a cross-over study with 27 patients compar-
ing single IM doses of buprenorphine and morphine, and found
no differences in ’maximum pain intensity difference’ between
the groups. However the ’total pain relief scores’ were signifi-
cantly greater after buprenorphine treatment thanmorphine treat-
ment, and the time to re-medication was significantly longer af-
ter buprenorphine (mean = 10 hours) than after morphine (mean
= eight hours) treatment. There were no differences between the
treatments in severity, onset and duration of euphoria, sweating,
blurred vision, thirst, sedation, deep respiration, decreased mem-
ory, numbness of hands and feet, headache, anxiety, feeling intox-
icated and feeling remote. However, dizziness, nausea and vomit-
ing were more severe, had earlier onset and longer duration after
treatment with buprenorphine compared to morphine (see Table
3).
IM buprenorphine + SC buprenorphine versus SC
buprenorphine versus placebo + SC buprenorphine
In a parallel-group trial lasting 48 hours, Noda 1989 compared
SC buprenorphine (4 µg/kg/day) preceded by an IM injection
of buprenorphine (0.004 µg/kg; N = 10) to SC buprenorphine
(4 µg/kg/day, N = 10) and to SC buprenorphine (8 µg/kg/day)
preceded by placebo infusion (N = 10). However, Noda 1989 un-
fortunately did not report the results clearly and inferentially anal-
ysed between the treatment groups. Descriptively, it appears that
pain intensity was lower, and comparable, in the groups receiving
the higher dose of SC buprenorphine or buprenorphine preceded
by IM buprenorphine compared to the group that received 4 µg/
kg/day SC buprenorphine (see Table 3 for the reported adverse
events).
Epidural buprenorphine versus epidural morphine
Pasqualucci 1987 compared single epidural doses of buprenor-
phine and morphine in a parallel-group trial with six patients in
each arm. This trial found no differences in pain scores after treat-
ment with either buprenorphine or morphine (see Table 3 for the
reported adverse events).
Intravenous buprenorphine versus intravenous
morphine
In a parallel-group study with treatment lasting 36 hours, Wang
2012 examined pain scores as assessed by a visual assessment scale
for patients who were treated with IV buprenorphine and who had
P-gp+ (P-glycoprotein; group B1; N = 30) and P-gp- (group B2;
N = 30) tumours and in patients who had received IV morphine
and who had P-gp+ (group M1; N = 30) and P-gp- (group M2;
N = 30) tumours. Wang 2012 reported that the VAS scores were
similar between the four groups at baseline (means (SDs): B1 =
7.8 (1.6); B2 = 7.9 (1.2); M1 = 8.0 (1.5); M2 = 8.1 (1.7)), but
then only included analyses between the groups that received the
same drug. Wang 2012 reported that the VAS scores of groups B1
and B2 all differed significantly from baseline, but did not differ
significantly from each other at four hours (means (SDs): B1 = 1.5
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(0.9); B2 = 1.6 (0.8)), 12 hours (means (SDs): B1 = 1.6 (0.7); B2 =
1.5 (1)), 24 hours (means (SDs): B1 = 1.4 (0.7); B2 = 1.4 (0.9)) or
36 hours (means (SDs): B1 = 1.5 (1); B2 = 1.4 (1.1)), whereas for
morphine the pattern of results was different. The VAS scores for
both groups M1 and M2 were significantly lower than baseline at
all times, but the pain scores were higher for group M1 compared
to groupM2 at four hours (means (SDs):M1 = 4.1 (2.4);M2 = 1.7
(1.1)), 12 hours (means (SDs): M1 = 4.4 (1.9); M2 = 1.8 (1.6)),
24 hours (means (SDs): M1 = 4.3 (1.6); M2 = 1.9 (1.4)) and 36
hours (means (SDs): M1 = 4.3 (2.3); M2 = 1.8 (1.4)). Groups M1
andM2 had received an identical dose of morphine (0.75 mg/kg).
A second set of analyses comparing group M2 to group M1 after
M1 had received a higher dose of morphine (1.1 mg/kg) showed
that the increased dose of morphine brought down the pain scores
of group M1 to levels that were comparable to those of group
M2 at all the times (means (SDs) for group M1 new: 8 (1.7) at
baseline; 1.8 (1.4) at four hours; 1.8 (1.9) at 12 hours; 1.7 (1.6) at
24 hours; 1.9 (1.8) at 36 hours), indicating that patients with P-
gp+ tumours are less sensitive to the analgesic effect of morphine
than patients with P-gp- tumours. Wang 2012 did not report on
adverse events.
D I S C U S S I O N
Summary of main results
In this review we identified 19 relevant studies that included a total
of 1421 patients and examined 16 different intervention compar-
isons. A number of these studies that performed comparative anal-
yses between the randomised groups found that buprenorphine
was superior in terms of pain relief/pain intensity reduction to the
comparison treatment (Bauer 1985, SL buprenorphine versus oral
tilidine with naloxone; De Conno 1987, SL buprenorphine versus
oral pentazocine (significantly more drowsiness with buprenor-
phine, but significantlymore dizziness and stomach painwith pen-
tazocine); Dini 1986, buprenorphine tablets (SL) and vials versus
pentazocine tablets and vials; Pace 2007; TD buprenorphine ver-
sus controlled-release morphine; Kjaer 1982, IM buprenorphine
versus IM morphine (although dizziness, nausea and vomiting
were more severe, had earlier onset and longer duration after treat-
ment with buprenorphine compared to morphine)), while three
studies found no differences between buprenorphine and the com-
parison drug (Pasqualucci 1987; epidural buprenorphine versus
epidural morphine; Rigolot 1979, IM buprenorphine versus IM
morphine; Yajnik 1992, SL buprenorphine versus SL buprenor-
phine + oral phenytoin versus phenytoin), and yet other studies
found treatment with buprenorphine to be inferior to the alterna-
tive treatment in terms of the side effects profile (Bono 1997, SL
buprenorphine versus oral tramadol; Sarhan 2009, TD buprenor-
phine versus TD fentanyl) or patient preference/ratings of accept-
ability (Brema 1996, SL buprenorphine versus slow-release tra-
madol).
Of the studies that compared different doses or formulations/
routes of administration of buprenorphine, pain intensity rat-
ings did not differ significantly between IM buprenorphine and
buprenorphine suppository.However, the average severity of dizzi-
ness, nausea, vomiting, and adverse events as a total were all signif-
icantly higher in the IM group relatively to the suppository group
(Dan 1989). SL buprenorphine was found to be associated with
faster onset of pain relief compared to SD buprenorphine, with
similar duration analgesia and no significant differences in adverse
event rates reported between the treatments (Limón Cano 1994).
In terms of TD buprenorphine, two studies found that it was su-
perior to placebo (Sittl 2003, placebo versus TD buprenorphine
at 35 µg/h, 52.5 µg/h, 70 µg/h; Poulain 2008, placebo versus
70 µg/h TD buprenorphine), whereas a third study found no
difference between placebo and different doses of TD buprenor-
phine (Böhme 2003 placebo versus TD buprenorphine at 35 µg/
h, 52.5 µg/h, 70 µg/h). Finally, the studies that examined differ-
ent doses of TD buprenorphine did also not report a clear dose-
response relationship (see also Summary of findings for the main
comparison).
Overall completeness and applicability of
evidence
The included19 studies reported on16different comparisons, and
there were only three comparisons with data from more than one
study. More specifically, these comparisons had data from two or
three studies, of all them comparing placebo toTDbuprenorphine
at different doses. However even in this group of four studies, two
studies (Böhme 2003; Sittl 2003) included patients with pain of
both malignant and non-malignant origin and did not report the
results separately for these two pain populations. The results of
Böhme 2003 and Sittl 2003 are therefore only applicable to the
current review to the extent that TD buprenorphine at the studied
doses and placebo have similar analgesic and safety profiles across
these two populations. Across all the studies the total number
of included patients ranged from 10 to 189, and all treatment
groups included less than 100 patients. The evidence base for
the effectiveness of buprenorphine in patients with cancer pain
may be considered to span a wide range of potential treatment
options, but at the expense of depth provided by large numbers
of patients treated within each comparison and replication of any
effects observed.
It should also be noted that not all the routes described are in com-
mon use in palliative and cancer care today. For instance, a num-
ber of trials assessed the IM route, which is now less commonly
utilised due to injections causing pain, and this route has been re-
placed by the SC route more commonly. However, in general trial
data including, for example, the TD and SL route is applicable, as
these are current acceptable and practical modes of delivery.
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Quality of the evidence
It is possible that the quality of the evidence is higher than it ap-
pears. This is because the evidence base generally suffers from a
large number of unreported details that may or may not indicate a
high risk of bias, had these methodological details been reported.
It is therefore very difficult to assess the extent that the results are
subject to different biases. For example, as inspection of Figure 2
indicates, only two of the included 19 trials clearly used an ap-
propriate randomisation sequence. We could not establish in any
of the studies that there had definitely been concealed allocation
to the treatment groups. On the other hand, we could only rate
one study at high risk of bias on the items dealing with selection
bias based on the reported details, which consequently leaves a
large amount of uncertainty for the remaining (vast majority of )
studies.
With data from91.8%of the total number of enrolled/randomised
patients analysed for pain, and from 85.6% of the patients anal-
ysed for safety, the results of this review are at moderate to high
risk of attrition bias. The observed attrition did not appear to be
selective over and beyond the results we have already reported of
any differences in ’discontinuation of treatment rates’ due to ad-
verse events. It is therefore conceivable that this bias exerts an equal
effect on the studied treatment comparisons.
Both the manner and the extent of outcome reporting observed
in the included studies also lead us to conclude that the results are
at some risk of reporting bias, with some studies not reporting all
expected outcomes and others reporting the outcomes in a format
that makes it impossible (or very difficult) to include them in any
data syntheses. This bias risk is perhaps not fully realised in this
Cochrane review due to the large number of different comparisons
that have only been considered by single studies (that are therefore
not meta-analysed). However future updates of this review may
include further studies examining the same comparisons and will
therefore be subject to a higher risk of reporting bias if all relevant
studies cannot be included in any resultant meta-analyses.
We also cannot exclude the possibility that our results are at some
(unknown) risk of publication bias, given the fact that most in-
cluded studies did not report null results (see also Potential biases
in the review process). We did include abstracts and perform a
comprehensive search of grey literature in order to minimise the
risk of publication bias in our review.
Finally, we note that some included studies had very small sample
sizes and are unlikely to be powered to reliably detect any poten-
tial real differences between the compared treatments. This may
also result in spurious findings that we are wary to treat as true
differences.
Potential biases in the review process
This Cochrane review included a number of studies that were
published in languages other than English. Although we did not
exclude any study for this reason, only one review author/transla-
tor extracted data and appraised these studies rather than two re-
view authors, as is the preferred standard for included studies. This
practice may have introduced author-specific bias into the process.
However, as already outlined above, in general the included stud-
ies were severely compromised by under-reporting with ’unclear’
judgements given in 125 (a total which excludes the 15 ’unclear’
rating of the item that only applied to the four cross-over trials) out
of 228 bias assessments. It is unlikely that these ratings (of which
there are more in the non-English language papers and in the ab-
stract) would change by double-reviewing as they reflect a clear
absence of information reported, and therefore the least judgment
of all the bias assessment ratings. Another potential source of bias
comes from the screening of search results process. We identified
one included study by chance very late in the review process (Noda
1989). Both review authors who screened the search results missed
this study because the title and abstract gave no (or very little) in-
dication that it was a RCT assessing three different buprenorphine
treatment strategies. Although we have checked other systematic
reviews on buprenorphine for relevant studies, its possible that we
have missed more relevant studies for this same reason.
Agreements and disagreements with other
studies or reviews
Given the absence of meta-analyses and the resultant narrative
summaries of the results of the included studies, it is perhaps un-
surprising that they tend to be in agreement in general with other
systematic reviews conducted on different but overlapping ques-
tions (e.g., Deandrea 2009 examining the role of TD buprenor-
phine in managing severe cancer pain; Tassinari 2008 examin-
ing the adverse effects of TD opioids compared to long-acting
morphine for moderate-severe cancer pain; Tassinari 2011 exam-
ining the use of TD opioids as front-line treatment for moder-
ate-severe cancer pain; Wolff 2012 examining the adverse events
of TD buprenorphine and fentanyl for chronic moderate-severe
pain). This is because their conclusions regarding buprenorphine
are based on equally limited evidence.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In clinical practice, morphine is accepted as the first-line strong
opioid of choice for the relief of cancer pain; other opioid anal-
gesics such as oxycodone and fentanyl are considered as second-
line options (NICE 2012). Side-effects can mean that one opi-
oid may need to be substituted with another opioid, so having a
wider ranging choice is practical. Furthermore, having a choice
with regard to route of administration can be of great importance
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in some patients, who, for example, are unable to swallow. Data
on the efficacy of buprenorphine compared to other opioids in
this Cochrane review was of varying, mostly low quality. However,
the available data demonstrate that it is an effective pain reliever
compared to comparison analgesics in the studies that were anal-
ysed. It performed less well in terms of side-effect profile when
compared to other analgesics, such as tramadol.
The results provide the treating clinician with limited data on the
efficacy of different routes of administration for buprenorphine.
Having said that, in those settings where buprenorphine is seen
to be an acceptable drug for treating cancer pain, a clinician may
decide that the type of pain may suit one deliverymode more than
another. For instance, a patient with pain specifically on move-
ment due to bone metastases may find it useful to have access
to SL buprenorphine prior to movement. Also, its quicker action
would make it a suitable medication to take, compared to having
an injection. It would also mean that the patient could use this
analgesic strategy at home, whereas the injectable route would be
more dependent on being delivered in a healthcare setting such as
a hospital ward or hospice.
Two studies found TD buprenorphine to be superior to placebo
(placebo versus TD buprenorphine at 35µg/h, 52.5µg/h, 70µg/
h; placebo versus 70 µg/h TD buprenorphine). However, a third
study found no difference between placebo and different doses
of TD buprenorphine (placebo versus TD buprenorphine at 35
µg/h, 52.5 µg/h, 70 µg/h). Studies examining different doses of
TD buprenorphine also did not report a clear dose-response re-
lationship, making recommendations on starting doses very dif-
ficult for the TD route. It also makes guidance on the titration
of TD buprenorphine difficult, in so far as it would have to be
initiated at the lowest dose, very gradually uptitrated and then
have varying, unpredictable efficacy, whereas the response from
another analgesics may be more easy to predict and control. TD
buprenorphine therefore becomes a less attractive choice for a pre-
scriber who wants to resolve cancer pain swiftly and efficiently.
In summary, clinicians who are faced with a choice of analgesics
to consider for cancer pain should use morphine as a first-line
on the grounds of price, at least until inferiority of morphine has
been established (NICE 2012). This Cochrane review did not
find sufficient evidence to make buprenorphine a valid first-line
choice alongside standard therapies like morphine, oxycodone and
fentanyl. However it has a place as an analgesic and its different
routes of administration maymake it a practical option for limited
types of cancer pain, for limited numbers of patient in limited
types of clinical setting.Where its place is exactly, is still hard to say.
It seems reasonable to suggest that it might be considered to rank
as a fourth-line option compared to the more standard therapies
like morphine, oxycodone and fentanyl, and even there it would
only be suitable for some patients. Having said that, palliative care
patients are often heterogeneous and complex, so having a number
of analgesics available that can be given differently increases patient
and prescriber choice. In particular, the SL and injectable routes
seemed to have a more definable analgesic effect, whereas the TD
route studies left more questions than they resolved.
Implications for research
Overall, the evidence was of poor quality. In a large number of
studies it was unclear whether an appropriate randomisation se-
quence had been used. Moreover, we could not establish in any of
the included studies whether there had definitely been concealed
allocation to the treatment groups. Any future research studies
should take this into account. Heterogeneity of methods and out-
come reporting was a further problem, which makes it very diffi-
cult to apply the current body of evidence to clinical and research
settings through further meta-analytic and summative analyses.
There is a need to establish efficacy and safety of buprenorphine in
its various formulations and routes, and its dose-response relation-
ship needs to be analysed further and compared to standard first-
line therapies, such as morphine sulphate, in adequately powered,
well-designed studies of sufficient duration in the setting of cancer
pain.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bauer 1985
Methods Design: Randomised, parallel group trial
Year: Not reported
Country: Germany
Participants Patients: 40 patients were randomised to one of the following groups:
• Buprenorphine: N = 20 females, mean age = 60.3 years.
• Tilidin-HCI + naloxon-HCI: N = 20 females, mean age = 54 years.
Inclusion criteria: “40 female patients were treated for severe cancer pain at the women’s
clinic at Heidelberg University.”
Exclusion criteria: Patients with severe liver or kidney damage, restriction of breathing
or respiratory regulation, increased intracranial pressure, or allergy to tilidin-HCI with
naloxone-HCl or buprenorphine
Interventions Buprenorphine arm:
• Drug: Buprenorphine hydrochloride.
• Dose/dosing: Single daily dose consisting of two tablets each giving a dose of 0.
216 mg buprenorphine hydrochloride (= 0.2 mg buprenorphine). The abstract reports
that it is a single daily dose, the methods section does not report any further details on
dosing, however the results suggest that it is not a single daily dose, but rather a fixed
dose given as needed.
• Formulation: SL.
• Route of administration: Oral.
• Length of treatment: 28 days.
• Titration schedule: No information reported.
• Rescue medication: No information reported.
• Other medication: No information reported.
Comparison arm:
• Drug: Tilidin-HCI + naloxon-HCI.
• Dose/dosing: Single daily dose consisting of two capsules each giving a dose of 50
mg tilidin-HCI and 4 mg naloxon-HCI. The abstract reports that it is a single daily
dose, the methods section does not report any further details on dosing. However the
results suggest that it is not a single daily dose, but rather a fixed dose given as needed.
• Formulation: Oral.
• Route of administration: Oral.
• Length of treatment: 28 days.
• Titration schedule: No information reported.
• Rescue medication: No information reported.
• Other medication: No information reported.
Outcomes • Pain intensity: Assessed by patients in the morning, at midday and in the evening
on days 0 (= before treatment), 1, 7, 14, 21 and 28 on a visual analogue scale.
• Side effects: No further details reported.
• Subjective evaluation of the drug: No further details reported.
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Bauer 1985 (Continued)
Notes • Study free of commercial funding? No information reported.
• Groups comparable at baseline? The groups were comparable in terms of weight,
height and baseline pain intensity. Unclear if they were balanced for age.
• ITT analyses undertaken? No information specifically reported, but the analyses
appear to be conducted as ITT.
• Study published in German and lay-translated by MSH.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study states it is randomised, but gives no
further details.
Allocation concealment (selection bias) Unclear risk See cell above.
Blinding of participants and personnel
(performance bias)
Pain
Unclear risk No details reported.
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk No details reported.
Blinding of outcome assessment (detection
bias)
Pain
Unclear risk No details reported.
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
Pain
Low risk Data from all 40 patients appear to be in-
cluded.
Incomplete outcome data (attrition bias)
Adverse events
Unclear risk Data not reported in a manner where this
can be ascertained.
Selective reporting (reporting bias) Unclear risk The outcomes are not well-reported.
Other bias Unclear risk It is unclear due to limited reporting
whether the study is subject to other bias
(es)
Were the patients adequately titrated? Unclear risk No details reported.
For cross-over trials: Are data available for
both time periods?
Unclear risk NA.
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Bono 1997
Methods Design: Randomised cross-over trial
Year: Not reported
Country: Italy
Participants Patients: 60 patients (with the following types of cancer: lung (N = 9), urological (N =
11), gynaecological (N = 3), blood-based (N = 2), ENT (N = 14), thoracic/oesophageal
(N = 8), skin (N = 1), gastrointestinal (N = 12)) were randomised to one of the following
2 groups (order of treatment):
• Tramadol-Buprenorphine: N = 30, 8 females/22 males, mean age (SD) = 62.6 (9.
9) years; mean duration of cancer (SD) = 16.3 (16.6) months, mean pain intensity
(SD) = 58 (28.3), mean Karnofsky performance status (SD) = 62.3 (19.6).
• Buprenorphine-tramadol: N = 30, 8 females/22 males, mean age (SD) = 60.2 (10.
7) years; mean duration of cancer (SD) = 16.9 (15.3) months, mean pain intensity
(SD) = 67.3 (25.3), mean Karnofsky performance status (SD) = 59.3 (19.1).
Inclusion criteria: “Sixty adults presenting with advanced tumours no longer responsive
to NSAIDs were included”
Exclusion criteria: Uncooperative patients, those with known intolerance to the test
drugs, with renal, respiratory or hepatic failure, associated chronic pathology, andwomen
in pregnancy or breast-feeding
Interventions Buprenorphine arm:
• Drug: Buprenorphine.
• Dose/dosing: 0.2 mg tablets 3 times a day to 0.6 mg buprenorphine per day.
• Formulation: SL.
• Route of administration: Oral
• Length of treatment: 7 days for each arm.
• Titration schedule: After a period of 7 days free of analgesic intake, the patients
took the study medications. No further information reported.
• Rescue medication: Patients could receive an additional study drug dose, if
necessary.
• Other medication: “Any concomitant medicinal products has been reported in
medical patient case file, specifying the name of the drug, the dose and duration of
treatment. Patients were not permitted to take morphine or monoamineoxidase
inhibitors but could take NSAIDs.”
Comparison arm:
• Drug: Tramadol.
• Dose/dosing: 100 mg tablets 3 times a day to 300 mg/day.
• Formulation: Oral.
• Route of administration: Oral.
• Length of treatment: 7 days for each arm.
• Titration schedule: After a period of 7 days free of analgesic intake, the patients
took the study medications. No further information reported.
• Rescue medication: Patients could receive an additional study drug dose, if
necessary.
• Other medication: “Any concomitant medicinal products has been reported in
medical patient case file, specifying the name of the drug, the dose and duration of
treatment. Patients were not permitted to take morphine or monoamineoxidase
inhibitors but could take NSAIDs.”
• For cross-over trials: Cross-over schedule: There was a 24-hour washout period
between the treatments.
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Bono 1997 (Continued)
Outcomes • Pain severity: Assessed by patients at baseline, at 15 mins, 30 mins, 1, 2, 3 and 4
hours after first drug administration and then every day at 1 hour after drug intake,
and every hour(?) on a 1-cm VAS (no pain on extreme left through to maximum pain
on extreme right) and on a comparative (to the previous day) pain scale (0 = almost
disappeared, 1 = slightly decreased, 2 = same, 3 = higher, 4 = much higher).
• Time spent asleep, including the quality of sleep (deep, good, bad; patient-
assessed).
• Adverse events.
• Global treatment efficacy/tolerability: Assessed the end of each of the two periods
of treatment by the investigator (overall assessment of efficacy) and patients (overall
assessment of tolerance of treatment) using a VAS (zero efficacy/tolerability on extreme
left through to maximum efficacy/tolerability on extreme right).
Notes • Study free of commercial funding? No information reported.
• Groups comparable at baseline? The groups appeared to be comparable at baseline
in terms of age, weight, gender distribution, illness duration and performance status,
but baseline pain severity appears to be higher in the buprenorphine-tramadol group.
• ITT analyses undertaken? The analyses do not appear to be conducted as ITT.
The study was published in French and lay translated by MSH.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported apart from that it
is a randomised study
Allocation concealment (selection bias) Unclear risk See cell above.
Blinding of participants and personnel
(performance bias)
Pain
Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk See cell above.
Blinding of outcome assessment (detection
bias)
Pain
Unclear risk See cell above.
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk See cell above.
Incomplete outcome data (attrition bias)
Pain
High risk Nine and 23 of the 60 patients discontin-
ued treatment during treatment with tra-
madol and buprenorphine, respectively
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Incomplete outcome data (attrition bias)
Adverse events
Low risk Data are reported for all included patients.
Selective reporting (reporting bias) Low risk All major outcomes are reported.
Other bias Unclear risk It is unclear if the study is subject to high
risk of other biases
Were the patients adequately titrated? Unclear risk It is unclear whether the patients were ad-
equately titrated based on the available in-
formation
For cross-over trials: Are data available for
both time periods?
High risk The pain intensity data did not appear to be
inferentially analysed collapsed over phases
for (any of ) the study days, apart from for
the first 4 hours of treatment, where no dif-
ferences were observed between the treat-
ments
Brema 1996
Methods Design: Randomised parallel group trial
Year: Not reported
Country: Italy
Participants Patients: 131 patients were randomised to one of the following 2 groups:
• Tramadol: N = 68, 32 females/36 males, mean age (SD, range) = 58.4 (10.1, 27-
79) years; type of cancer: lung (N = 18), digestive tract (N = 20), breast (N = 8),
urogenital tract (N = 9), cervico-facial (N = 3), other (N = 10); 40 patients had
metastasis; discontinuation of treatment before the 6-month period was completed due
to poor tolerance (N = 6), lack of effect (N = 16), disease progression or death (N = 27)
, pain reduction (N = 4), poor compliance (N = 2), and various reasons (N = 8). 32.3%
of the drop-outs occurred in the first 2 weeks. Only 4 patients completed the 6 months
of treatment.
• Buprenorphine: N = 63, 13 females/50 males, mean age (SD, range) = 60.1 (11.6,
29-82) years; type of cancer: lung (N = 18), digestive tract (N = 17), breast (N = 6),
urogenital tract (N = 11), cervico-facial (N = 6), other (N = 5); 35 patients had
metastasis; discontinuation of treatment before the 6-month period was completed due
to poor tolerance (N = 7), lack of effect (N = 24), disease progression or death (N = 22)
, pain reduction (N = 2), poor compliance (N = 3), and various reasons (N = 4). 30.2%
of the drop-outs occurred in the first 2 weeks. Only 1 patient completed the 6 months
of treatment.
Inclusion criteria: ”Adults with [neoplastic] pain no longer responsive to regular treat-
ment with non-steroidal antiinflammatory drugs (NSAIDs) were admitted.“
Exclusion criteria: ”Uncooperative patients, those with known intolerance to the test
drugs, with renal, respiratory or hepatic failure, taking morphine, major analgesics or
monoamine oxidase inhibitors, and women in pregnancy or breast-feeding, were con-
sidered ineligible.“
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Interventions Buprenorphine arm:
• Drug: Buprenorphine.
• Dose/dosing: 0.2 mg buprenorphine in one tablet every 6 to 8 hours.
• Formulation: SL.
• Route of administration: Oral.
• Length of treatment: Up to 6 months.
• Titration schedule: No information reported.
• Rescue medication: ”When the test drugs did not provide adequate pain relief at
the maximum specified dose, paracetamol could be given as well, up to 4 g/day.“
• Other medication: ”All therapies required to control the basic pathology were
continued“.
Comparison arm:
• Drug: Tramadol.
• Dose/dosing: 100 mg tablet every 8 to 12 hours up to a maximum of 400 mg/day.
• Formulation: Slow-release.
• Route of administration: Oral.
• Length of treatment: Up to 6 months.
• Titration schedule: No information reported.
• Rescue medication: ”When the test drugs did not provide adequate pain relief at
the maximum specified dose, paracetamol could be given as well, up to 4 g/day.“
• Other medication: ”All therapies required to control the basic pathology were
continued“.
Outcomes • Pain severity: Assessed by patients at baseline, on days 7 and 14, and monthly
thereafter on a 6-point rating scale (0 = none, 1 = mild, 2 = moderate, 3 = strong, 4 =
very strong, 5 = unbearable) and the type of pain was evaluated on a semantic scale
(throbbing, fulgurating, lancinating, cutting, pressing, crushing, burning, ”pins and
needles“, terebrant, crampy, piercing). For the first 2 weeks of the study, pain severity
was also evaluated by the patients on a 10-cm visual assessment scale at baseline, 15
min, 30 min, 1, 2, 3 and 4 hours after the first dose and then daily thereafter.
• Degree of pain relief compared to the previous day: Assessed by patients for the
first 2 weeks of the study on a 5-point rating scale (0 = almost disappeared, 1 = slightly
less, 2 = the same, 3 = more severe, 4 = much more severe).
• Quality of sleep: Assessed by patients for the first 2 weeks of the study on a 5-
point rating scale (0 = no sleep, 1 = frequent wakings, 2 = poor, 3 = good, 4 = deep).
• Adverse events: ”Any adverse events arising during the trial were recorded, noting
their time of onset, severity, duration, relation with the test drugs and measures
adopted.
• Treatment acceptability: Assessed by patients at the end of first 14 days of
treatment and after 6 months on a 10-cm visual assessment scale (marked at the right-
hand end with “maximum acceptability”, and at the left-hand end with “completely
unacceptable”).
• Quality of life: Assessed at baseline, day 14 and monthly hereafter using Spitzer’s
scheme.
Notes • Study free of commercial funding? No information reported.
• Groups comparable at baseline? The groups appeared to be comparable at baseline
in terms of age, weight, height, baseline pain severity, tumour site and metastasis,
Karnofsky performance status, and duration of disease, but did differ significantly in
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gender distribution.
• ITT analyses undertaken? The analyses appear to be conducted as ITT.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “On the basis of the randomization list,
each patientwas assigned to treatment”.No
further information reported
Allocation concealment (selection bias) Unclear risk See cell above.
Blinding of participants and personnel
(performance bias)
Pain
Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk See cell above.
Blinding of outcome assessment (detection
bias)
Pain
Unclear risk See cell above.
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk See cell above.
Incomplete outcome data (attrition bias)
Pain
Low risk Data from all patients appear to be in-
cluded.
Incomplete outcome data (attrition bias)
Adverse events
Low risk Data from all patients appear to be in-
cluded.
Selective reporting (reporting bias) Low risk The main outcomes are reported.
Other bias Unclear risk It is unclear whether the study is at high
risk of other bias(es)
Were the patients adequately titrated? Unclear risk No information is reported.
For cross-over trials: Are data available for
both time periods?
Unclear risk NA.
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Böhme 2003
Methods Design: Randomised, double-blind, parallel group trial
Year: Not reported
Country: Austria, Germany, and Hungary
Participants Patients: 189 patients entered the run-in phase, of these 38 were excluded and 151
patients were randomised to one of the following 4 groups:
• Placebo: N = 37, 18 females/19 males, mean age (SD) = 54.9 (11.5) years; 20 had
malignant pain origin/17 had non-malignant pain origin; frequency of additional
analgesic, anti-inflammatory agent and anti-pyretic use (WHO step 1) = 54% of
patients; number of patients prematurely withdrawn from the study = 3.
• Buprenorphine 35 µg/h: N = 35, 18 females/17 males, mean age (SD) = 60.6 (12.
2) years; 22 had malignant pain origin/13 had non-malignant pain origin; frequency of
additional analgesic, anti-inflammatory agent and anti-pyretic use (WHO step 1) =
71% of patients; number of patients prematurely withdrawn from the study = 2.
• Buprenorphine 52.5 µg/h: N = 41, 21 females/20 males, mean age (SD) = 60.5
(13) years; 22 had malignant pain origin/19 had non-malignant pain origin; frequency
of additional analgesic, anti-inflammatory agent and anti-pyretic use (WHO step 1) =
63% of patients; number of patients prematurely withdrawn from the study = 5.
• Buprenorphine 70 µg/h: N = 38, 24 females/14 males, mean age (SD) = 62.7
(11) years; 19 had malignant pain origin/19 had non-malignant pain origin; frequency
of additional analgesic, anti-inflammatory agent and anti-pyretic use (WHO step 1) =
63% of patients; number of patients prematurely withdrawn from the study = 3.
90 to 93% of the patients in the treatment arms had been prescribed strong opioids
(WHO step 3), 0 to 8% in each treatment arm used weak opioids (WHO step 2)
Inclusion criteria: “The main inclusion criteria for the double-blind phase was chronic
pain that was at least satisfactorily relieved (according to a verbal rating scale) with 0.8-
1.2 mg/day sublingual buprenorphine after a 5-day run-in phase.”
Exclusion criteria: “Exclusion criteria were alcohol or drug abuse, hypersensitivity to-
wards opioids, compromised respiratory function, a history of convulsions, raised in-
tracranial pressure, and previous extensive damage to the dermis in the patch application
area (subclavicular chest or upper back regions). Also excluded were patients receiving
local radionucleotide therapy, opioids other than sublingual buprenorphine, or MAO-
inhibitors.”
Interventions Buprenorphine arms (3):
• Drug: Buprenorphine.
• Dose/dosing: 35 µg/h or 52.5 µg/h or 70 µg/h buprenorphine administered in 2
patches applied consecutively for 72 hours each to the subclavicular chest or upper
back region of each patient. “Because of the delayed onset of analgesia due to patch
technology with buprenorphine TDS, patients continued to take prescribed sublingual
buprenorphine on the first day of the double-blind treatment phase, day 6.
• Formulation: TD.
• Route of administration: TD patch.
• Length of treatment: 6 days (study days 6 to 11; study days 12 to 15 comprised
the washout phase).
• Titration schedule: ”Patients first entered an open run-in phase (days 1-5), during
which they took sublingual buprenorphine 0.8-1.2 mg/day at prescribed doses and
times....If this analgesic regimen produced satisfactory pain relief (VRS), patients were
randomised to one of four study arms and entered the double-blind phase (days 6-15).“
• Rescue medication: ”From day 7 onwards, patients took 0.2 mg sublingual
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Böhme 2003 (Continued)
buprenorphine tablets only as required for the relief of breakthrough pain.“
• Other medication: ”Opioids other than the study medication were prohibited,
while non-excluded concomitant medications were continued at fixed doses.“
Comparison arm:
• Drug: Placebo
Apart from study drug everything else was similar to the buprenorphine arms
Outcomes • Pain intensity: Assessed by patients at 8.00 and 20.00 and during interviews on
days 1, 6, 9, 12 and 15 on a 5-point verbal rating scale. Pain intensity was categorised
as absent, slight, moderate, severe or very severe.
• Pain relief: Assessed by patients during interviews on days 1, 6, 9, 12 and 15 on a
4-point verbal rating scale. ”Pain relief was categorised as unsatisfactory, satisfactory,
good or complete.
• Duration of sleep uninterrupted by pain the previous night: Assessed by patients
at 8.00 and 20.00 on a 4-point verbal rating scale with the following categories: > 6, 3
to 6, 2 to 3, or < 2 hours.
• Responding patients “defined as those whose pain relief was at least satisfactory at
all determination points (excluding the final examination) and who took a mean of 0.2
mg/day or less of sublingual buprenorphine on days 7-12. Patients who prematurely
withdrew from the study due to adverse events, unsatisfactory pain relief or for unclear
reasons were classed as non-responders.”
• Adverse events: Systemic AE recorded throughout the trial, patch-related AE
assessed at patch change (including swelling, erythema, pruritus, signs of infection,
other dermal damage).
Notes • Study free of commercial funding? “This study was supported by Grunenthal
GmbH, Aachen, Germany.”
• Groups comparable at baseline? “There were no significant differences at baseline
between treatment groups in demographic parameters, although patients in the
placebo group were younger than those in the other treatment groups (p = 0.0079)”.
• ITT analyses undertaken? Unclear.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
Pain
Unclear risk Study described as double-blind. Unclear
who is blinded.
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk See cell above.
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Blinding of outcome assessment (detection
bias)
Pain
Low risk See cell above. Pain is patient reported.
Probably reasonable to assume that patients
were blinded
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk Study described as double-blind. Unclear
who is blinded and whether this outcome
is assessed by healthcare professionals also
Incomplete outcome data (attrition bias)
Pain
Low risk The analyses appear to include 149/151 pa-
tients.
Incomplete outcome data (attrition bias)
Adverse events
Low risk The analyses appear to include 151/151 pa-
tients.
Selective reporting (reporting bias) Low risk All obvious outcomes appear to be re-
ported.
Other bias Low risk No other obvious biases were observed.
Were the patients adequately titrated? Low risk Probably.
For cross-over trials: Are data available for
both time periods?
Unclear risk NA.
Dan 1989
Methods Design: Randomised, double-blind, parallel group trial
Year: July 1987 to March 1988
Country: Japan
Participants Patients: 73 patients were randomised to one of the following 2 groups:
• Buprenorphine suppository: N = 34, 15 females/19 males, age: < 60 years (14),
60-70 years (11), ≥70 years (9); cancer type: stomach (8), hepato-biliary-pancreatic (7)
, colorectal-uterine (4), breast-prostate (5), oropharyngeal (2), lung (4), oesophageal
(2), other (2); analgesic drugs: none (0) peripheral analgesic (25), peripheral+central
analgesic (6), central analgesic (2), others (1); pain intensity at baseline: mild (17),
moderate (17); ECOG performance status: 0 (2), 1 (3), 2 (11), 3 (13), 4 (5); number
of patients excluded from the study = 2 (due to protocol violations consisting of
treatment with other analgesic agents and/or severe pain).
• Buprenorphine injection: N = 35, 10 females/25 males, age: <60 years (20), 60≤
and <70 (9), 70≤ years (6); cancer type: stomach (10), hepato-biliary-pancreatic (7),
colorectal-uterine (4), breast-prostate (3), oropharyngeal (5), lung (2), oesophageal (1),
other (3); analgesic drugs: none (1) peripheral analgesic (22), peripheral+central
analgesic (6), central analgesic (5), others (1); pain intensity at baseline: mild (17),
moderate (18); ECOG performance status: 0 (1), 1 (6), 2 (10), 3 (17), 4 (2); number
of patients excluded from the study = 1 (due to protocol violations consisting of
treatment with other analgesic agents).
Inclusion criteria: “Patient who have a cancer pain and pain intensity is 2 (mild) or 3
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(moderate)”
Exclusion criteria: None reported.
Interventions Buprenorphine suppository:
• Drug: Buprenorphine suppository + placebo injection.
• Dose/dosing: 0.2 mg administered twice, with the second administration 6 to 8
hours after the first administration regardless of the presence or absence of pain.
• Formulation: Suppository.
• Route of administration: Intra-rectal.
• Length of treatment: 12 to 16 hours.
• Titration schedule: No information reported.
• Rescue medication: Appears to be indomethacin suppository 50 mg. Study drug
must be administered > 4 hours after using indomethacin suppository (no further
information reported).
• Other medication: Other analgesics or suppositories should not be used, and the
authors avoided the use of psychotropic drugs as they appear to affect the action of the
experimental drugs.“
Buprenorphine injection:
• Drug: Buprenorphine injection + placebo suppository.
• Dose/dosing: 0.2 mg administered twice, with the second administration 6-8
hours after the first administration regardless of the presence or absence of pain.
• Formulation: Injection.
• Route of administration: IM.
• Length of treatment: 12 to 16 hours.
• Titration schedule: No information reported.
• Rescue medication: Appears to be indomethacin suppository 50 mg. Study drug
must be administered > 4 hours after using indomethacin suppository (no further
information reported).
• Other medication: Other analgesics or suppositories should not be used, and the
authors avoided the use of psychotropic drugs as they appear to affect the action of the
experimental drugs.”
Outcomes • Pain intensity: Assessed by patients at baseline and at 2, 4 and 6 hours in response
to the question “How is your pain”. It seems the patient answers were then coded into
one of 4 categories: 1 = none or little pain (“I have no pain” “I have a little pain, but it
does not bother me”), 2 = mild pain (“I can stand the pain, but it always bother me”),
3 = moderate pain (“I can barely stand the pain, it is quite painful”), and 4 = severe
pain (“I have intolerable, quite painful pain that I cannot stand”).
• Pain relief: Assessed by patients at baseline and at 2, 4 and 6 hours in response to
the question “How is the effect”. It seems the patient answers were then coded into one
of 3 categories: 1 = effective (“Drug has worked well” “I have a little pain, but drug has
worked well”), 2 = minor response (“Drug has not worked much”), 3 = ineffective
(“Drug has not worked at all”).
• Adverse events including appetite (assessed at baseline and study end), temper
(assessed at baseline and study end), drowsiness,dizziness, feeling heavy-headed,
nausea, vomiting, sweating, thirst, urinary retention, euphoria, and fatigue (all assessed
12 hours after second experimental drug administration): Assessed by healthcare
professional on a scale from 0 (no symptom) to 3 (severe; for dizziness, feeling heavy-
headed, nausea, vomiting, sweating, thirst, urinary retention, euphoria, and fatigue),
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and on a scale from 0 (no symptom) to 4 (severe; for drowsiness).
Notes • Study free of commercial funding? Not reported.
• Groups comparable at baseline? Yes, the groups appear to be comparable at
baseline.
• ITT analyses undertaken? No, the analyses were conducted per-protocol.
This study is only published in Japanese, andwas kindly translated byDr.MakiKawasaki,
Japanese Branch of the Australasian Cochrane Centre
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information about randomisa-
tion sequence to make a judgement
Allocation concealment (selection bias) Unclear risk Insufficient information about allocation
to make a judgement
Blinding of participants and personnel
(performance bias)
Pain
Low risk Double-blinded and placebo looks identi-
cal to the actual drug
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk Double-blinded and placebo looks identi-
cal to the actual drug
Blinding of outcome assessment (detection
bias)
Pain
Low risk Assessed by patients and they were blinded.
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk Assessed by healthcare professional and
they were blinded.
Incomplete outcome data (attrition bias)
Pain
High risk Data reported for 28/35 IM patients and
33/34 rectal buprenorphine patients after
the second administration of the study drug
Incomplete outcome data (attrition bias)
Adverse events
Low risk Most of the adverse events appear to be re-
ported for 34/34 rectal buprenorphine pa-
tients and for 35/35 IM buprenorphine pa-
tients
Selective reporting (reporting bias) Low risk All the main expected outcomes are re-
ported.
Other bias Unclear risk It is unclear whether the study is at risk of
other bias(es)
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Were the patients adequately titrated? Unclear risk It is unclear, but probably not.
For cross-over trials: Are data available for
both time periods?
Unclear risk NA.
De Conno 1987
Methods Design: Randomised cross-over trial
Year: Not reported
Country: Italy
Participants Patients: 120 patients were randomised and 29 did not complete treatment (10/29
patients suspended both treatments, 16/29 patients suspended pentazocine and 3/29
suspended buprenorphine): No patient characteristics are reported
Inclusion criteria: Patients with cancer pain of moderate to severe intensity aged > 18
years who have given informed consent
Exclusion criteria: Severe renal or hepatic impairment, severe respiratory failure, chronic
treatment with high doses of agonist analgesics, increase in intracranial pressure, preg-
nancy
Interventions Buprenorphine:
• Drug: Buprenorphine SL tablets 0.2 mg.
• Dose/dosing: 1 to 2 tablets of 0.2 mg administered every 6 to 8 hours depending
on need.
• Formulation: SL.
• Route of administration: SL.
• Length of treatment: 7 days.
• Titration schedule: No information reported.
• Rescue medication: No information provided.
• Other medication: No information provided.
Pentazocine:
• Drug: Tablets 50 mg.
• Dose/dosing: 1 to 2 tablets of 50 mg administered every 6 to 8 hours depending
on need.
• Formulation: Oral.
• Route of administration: Oral.
• Length of treatment: 7 days.
• Titration schedule: No information reported.
• Rescue medication: No information provided.
• Other medication: No information provided.
• For cross-over trials: Cross-over schedule: There was no wash-out period either at
the beginning of the study or between treatments. The first 7-day stage was followed
immediately by the second 7-day stage.
Outcomes • Pain intensity: Assessed by patients and their relatives daily on a 5-point
categorical scale: 1 = slight pain, 2.5 = moderate/troublesome pain, 5 = severe/
exhausting pain, 7.5= terrible pain, 10 = excruciating/killing pain.
• Number of hours slept, number of hours pain free, and number of hours assessed
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as any of the pain categories above. The total number of hours must add up to 24 hours.
• Number of hours spent standing, sitting or lying.
• Side effects: Nausea, vomiting, drowsiness, agitation vertigo, tremors, dry mouth,
sweating, itching , allergy and headache (all recorded daily).
• 16 patients of the whole sample who completed both treatments data on the
quality of life were also collected through: 1) Karnofsky performance status; 2) hours of
work activities; 3) hours of evasion; 4) hours of inactivity. These data are not reported
as it is unclear how these patients were selected and what their characteristics are.
Notes • Study free of commercial funding? Not clear, the information reported for the
author affiliations is ambiguous and may include the manufacturer of buprenorphine.
• Groups comparable at baseline? Unclear, no information reported.
• ITT analyses undertaken? It does not appear that the analyses were conducted as
ITT.
This study is published in two papers, the earlier paper is in English and includes a smaller
sample than the later paper, which is published in Italian and lay-translated by MSH.
The data from this newer paper which reports the larger sample have been included
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
Pain
Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk No information reported.
Blinding of outcome assessment (detection
bias)
Pain
Unclear risk No information reported.
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk No information reported.
Incomplete outcome data (attrition bias)
Pain
High risk Data only available for 91/120 randomised
patients.
Incomplete outcome data (attrition bias)
Adverse events
High risk See cell above.
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Selective reporting (reporting bias) Unclear risk The outcomes are not well-reported.
Other bias Unclear risk It is unclear whether the study is at high
risk of other biases
Were the patients adequately titrated? High risk The patients were not titrated at the begin-
ning of the actual study
For cross-over trials: Are data available for
both time periods?
Low risk Yes, for a number of participants.
Dini 1986
Methods Design: Randomised parallel-group trial
Year: Not reported
Country: Italy
Participants Patients: Patients divided into two group: Group Tablet and group Vial (fluid). Within
each of these groups patients were allocated to treatment with either buprenorphine or
pentazocine:
• Group Tablet: 9 males/12 females; mean age = 59 years; cancer type: breast (6),
prostate (2), rectal (3), oral cavity (3), bladder (1), uterine (1), laryngeal (1),
hypopharynx (1), lung (1), ovarian (1), anal (1). 11 patients were treated with
buprenorphine and 10 with pentazocine. 11 patients were treated with buprenorphine
and 10 with pentazocine.
• Group Vial (fluid): 12 males/9 females; mean age = 59 years; cancer type: breast
(4), gastric (1), rectal (3), lung (3), bladder (1), transverse colon (1), sigmoid colon (1),
papiloma of nasal cavity (1), parotid (1), renal (1), uterine (1), sarcoma of the thigh (1)
, undetermined (2). 11 patients were treated with buprenorphine and 10 with
pentazocine.
Inclusion criteria: 42 patients aged > 18 years with pain of moderate-severe intensity of
neoplastic origin was selected by/fromThe Center for Pain Management at the National
Institute of Cancer Research
Exclusion criteria: Severe renal or hepatic impairment, severe respiratory failure, pre-
vious treatment with agonist analgesics, intracranial hypertension, mental confusion,
pregnancy/lactation
Interventions Buprenorphine tablets:
• Drug: Buprenorphine SL tablets 0.2 mg.
• Dose/dosing: 1 to 2 tablets of 0.2 mg administered every 6 to 8 hours depending
on need.
• Formulation: SL.
• Route of administration: Oral.
• Length of treatment: 7 days.
• Titration schedule: No information reported.
• Rescue medication: No information provided.
• Other medication: No information provided.
Buprenorphine vials/fluid:
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• Drug: Vials 0.3 mg.
• Dose/dosing: 1 vial of 0.3 mg administered at a dose of 1 to 3 vials a day,
depending on the severity of the case (mean daily dose was 1.7 vials).
• Formulation: Oral.
• Route of administration: Oral.
• Length of treatment: 7 days.
• Titration schedule: No information reported.
• Rescue medication: No information provided.
• Other medication: No information provided.
Pentazocine tablets:
• Drug: Tablets 50 mg.
• Dose/dosing: 1 tablet of 50 mg administered at a dose of 3 tablets a day.
• Formulation: Oral.
• Route of administration: Oral.
• Length of treatment: 7 days.
• Titration schedule: No information reported.
• Rescue medication: No information provided.
• Other medication: No information provided.
Pentazocine vials/fluid:
• Drug: Vials 30 mg
• Dose/dosing: 1 vial of 30 mg administered at a dose of 1 to 3 vials a day (mean
daily dose was 2.2 vials).
• Formulation: Oral.
• Route of administration: Oral.
• Length of treatment: 7 days.
• Titration schedule: No information reported.
• Rescue medication: No information provided.
• Other medication: No information provided.
Outcomes • Pain intensity: Assessed by patients(?) daily on a 6-point categorical scale: 0 = no
pain, 1 = mild pain, 2.5 = moderate pain, 5 = some considerable pain, 7.5= strong
pain, 10 = unbearable pain.
• Number of hours slept, number of hours pain free, and number of hours assessed
as any of the pain categories above.
• “Daily integrated intensity and duration of pain score” calculated by (1)
calculating the exact number of hours of pain, (2) multiplying the number of hours by
the values corresponding to the intensity of the pain experienced, (3) summing the
products, and (4) dividing the total by the number of days of treatment.
• Number of hours spent upright, and supine (whether sleeping or not).
• Effectiveness of treatment: Assessed by patients(?) on a 5-point categorical scale:
excellent, good, fair, poor, nothing.
• Tolerability of treatment: Assessed by patients(?) on a 4-point categorical scale:
excellent, good, fair, poor.
• Side effects.
Notes • Study free of commercial funding? Unclear, the information reported for the
author affiliations is ambiguous and may include the manufacturer of buprenorphine.
• Groups comparable at baseline? Unclear, very limited information reported.
• ITT analyses undertaken? It is not clear whether the analyses were conducted as
ITT.
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This study is published in Italian and lay-translated by MSH
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No informationother than that the patients
were randomised is reported
Allocation concealment (selection bias) Unclear risk See cell above.
Blinding of participants and personnel
(performance bias)
Pain
Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk See cell above.
Blinding of outcome assessment (detection
bias)
Pain
Unclear risk See cell above.
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk See cell above.
Incomplete outcome data (attrition bias)
Pain
Unclear risk It is unclear whether any data are missing.
Incomplete outcome data (attrition bias)
Adverse events
Unclear risk See cell above.
Selective reporting (reporting bias) Low risk The main expected outcomes appear to be
reported.
Other bias Unclear risk It is unclear whether the study is subject to
high risk of other types of bias
Were the patients adequately titrated? Unclear risk No information reported.
For cross-over trials: Are data available for
both time periods?
Unclear risk NA.
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Methods Design: Randomised, double-blind, cross-over trial
Year: Not reported
Country: Denmark
Participants Patients: 27patientswere randomised, 26patients completed the study andwere included
in the safety analyses (1 patient withdrew to receive treatment for bone metastases), and
25 patients were included in the efficacy analyses (1 patient was excluded due to being
remedicated by mistake): 13 males/14 females; mean age (range) = 60 (41 to 71) years;
Type of cancer: lung (N = 12), breast (N = 7), female genital system (N = 4), head
and neck (N = 3), oesophagus (N = 1). 13/27 received buprenorphine first and 14/27
received morphine first
Inclusion criteria: “None of the patients hadpreviously received regular doses of narcotics.
The basis for selection of patients to the study was persistent pain where aspirin, dextro-
propoxyphene or paracetamolwere no longer effective in controlling the pain. All patients
gave informed consent to participate in the study and agreed to at least 3 full days in
hospital.”
Exclusion criteria: “Patients with severe renal damage (serum creatinine ≥ 120 µmol/
L), and severe hepatic damage (serum bilirubin ≥ 17 µmol/L, plasma aspartate amino-
transferase ≥ 50 U/L, plasma alkaline phosphatase ≥ 275 U/L, plasma lactate dehydro-
genase ≥ 450 U/L) were not included in the study. Neither were patients with marked
ventilatory impairment or persistent mental confusion.”
Interventions Buprenorphine arm:
• Drug: Buprenorphine.
• Dose/dosing: 0.3 mg buprenorphine in a 1 mL ampoule.
• Formulation: IM.
• Route of administration: IM injection.
• Length of treatment: Single dose.
• Titration schedule: No titration.
• Rescue medication: “Seven patients in the buprenorphine group were remedicated
with an analgesic agent before 8 h compared with ten patients in the morphine group”.
No further information provided.
• Other medication: “No analgesic or sedative was administered less than 6.5 h
prior to study medication. Drugs allowed during the test period were the following: -
aspirin 1000 mg, paracetamol 1000 mg, diazepam 5 mg. All other medications were
recorded.”(?)
Comparison arm:
• Drug: Morphine.
• Dose/dosing: 10 mg morphine in a 1 mL ampoule.
• Formulation: IM.
• Route of administration: IM injection.
• Length of treatment: Single dose.
• Titration schedule: No titration.
• Rescue medication: “Seven patients in the buprenorphine group were remedicated
with an analgesic agent before 8 h compared with ten patients in the morphine group”.
No further information provided.
• Other medication: “No analgesic or sedative was administered less than 6.5 h
prior to study medication. Drugs allowed during the test period were the following: -
aspirin 1000 mg, paracetamol 1000 mg, diazepam 5 mg. All other medications were
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recorded.”(?)
• For cross-over trials: Cross-over schedule: “The second injection was administered
24 h after the first”.
Outcomes • Pain intensity: Assessed by nurse observer/patients immediate before, and 0.25, 0.
5, 1, 1.5, 2, 3, 4, 5 and 6 hours after drug administration on a 4-point categorical scale
(0 = none, 1 = slight, 2 = moderate, 3 = severe).
• Pain relief: Assessed by nurse observer/patients immediate before, and 0.25, 0.5,
1, 1.5, 2, 3, 4, 5 and 6 hours after drug administration on a 5-point categorical scale (0
= none, 1 = slight, 2 = moderate, 3 = good, 4 = complete).
• Degree of sedation: Assessed by nurse observer/patients immediate before, and 0.
25, 0.5, 1, 1.5, 2, 3, 4, 5 and 6 hours after drug administration on a 4-point categorical
scale (0 = alert, 1 = mildly drowsy, 2 = moderately drowsy, 3 = asleep).
• Severity of side effects: Assessed by nurse observer/patients immediate before, and
0.25, 0.5, 1, 1.5, 2, 3, 4, 5 and 6 hours after drug administration on a 3-point
categorical scale (1 = mild, 2 = moderate, 3 = severe), for dizziness, euphoria, nausea,
vomiting, blurred vision, thirst, sedation, deep respiration, decreased memory,
numbness of hands and feet, headache, perspiration, feeling intoxicated, anxiety,
feeling remote.
Notes • Study free of commercial funding? “The authors want to thank the Clinical
sciences Department, Pharmaceutical Division, Reckitt & Colman for the supply of
drugs and the statistical evaluation of the results”.
• Groups comparable at baseline? “Comparison of the two groups of patients
according to randomization sequence with regard to sex, age and weight showed no
significant differences”.
• ITT analyses undertaken? The analyses appear to be conducted as ITT.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
Pain
Low risk Study described as double-blind. “Individ-
ual treatments were supplied in identical
coded ampoules (1 ml) containing either
buprenorphine (0.3 mg) or morphine (10
mg). Each treatment pack consisted of two
ampoules labelled A and B which were ad-
ministered in alphabetical order. The order
of treatments were randomized bothwithin
and between patients.”
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Blinding of participants and personnel
(performance bias)
Adverse events
Low risk See cell above.
Blinding of outcome assessment (detection
bias)
Pain
Low risk See cell above.
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk See cell above.
Incomplete outcome data (attrition bias)
Pain
Low risk The analyses included 25/27 patients for
efficacy.
Incomplete outcome data (attrition bias)
Adverse events
Low risk The analyses included 26/27 patients for
safety.
Selective reporting (reporting bias) Low risk The main expected outcomes are reported,
although not in a manner that allow their
inclusion in a meta-analysis
Other bias Unclear risk It is unclear whether the study is subject to
other types of bias
Were the patients adequately titrated? High risk There was no titration.
For cross-over trials: Are data available for
both time periods?
Low risk The data appear to be available for both
periods.
Limón Cano 1994
Methods Design: Randomised, double-blind, parallel-group trial
Year: Not reported
Country: Mexico
Participants Patients: 17 patients (11 males/6 females) were randomised to one of the following two
groups:
• SL buprenorphine: N = 10; mean age (SD?) = 53.2 (17.8) years.
• SD buprenorphine: N = 7; mean age (SD?) = 49.1 (17.1) years.
Inclusion criteria: 17 patients withmoderate to severe cancer pain that had not responded
to treatment with non-opioid and adjuvant analgesics according to the WHO analgesic
ladder
Exclusion criteria: Patients with liver damage, renal or severe cardiorespiratory problems
Interventions SL buprenorphine arm:
• Drug: Buprenorphine.
• Dose/dosing: 0.2 to 0.4 mg buprenorphine in 1 to 2 tablets + 0.5 to 1 mL placebo
49Buprenorphine for treating cancer pain (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Limón Cano 1994 (Continued)
SD injection from SD catheter in the anterior thorax.
• Formulation: SL.
• Route of administration: SL.
• Length of treatment: 24 hours it seems. “Subsequent doses were administered
according to the requirements of the patients within a time interval of 4-8 hours”.
• Titration schedule: No titration.
• Rescue medication: No information provided.
• Other medication: No information provided.
SD buprenorphine arm:
• Drug: Buprenorphine.
• Dose/dosing: 0.15 to 0.3 mg buprenorphine in 0.5 to 1 mL SD injection from
SD catheter in the anterior thorax and 1 to 2 SL placebo tablets.
• Formulation: SD.
• Route of administration: SD.
• Length of treatment: 24 hours, it seems. “Subsequent doses were administered
according to the requirements of the patients within a time interval of 4-8 hours”.
• Titration schedule: No titration.
• Rescue medication: No information provided.
• Other medication: No information provided.
Outcomes “The analgesic response (decrease in pain intensity according to visual analogue scale),
latency and duration of analgesia, side effects and difficulties to appreciate the procedure
[patient preference?].”
Notes • Study free of commercial funding? No information reported.
• Groups comparable at baseline? The groups were comparable in terms of weight
and height and baseline pain intensity. Unclear if they were balanced for gender and
age.
• ITT analyses undertaken? No information specifically reported, but the analyses
appear to be conducted as ITT.
Study published in Spanish and lay-translated by MSH.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The allocation to each treatment group: SL
and SD was randomised and the study was
double blind. No further information re-
ported
Allocation concealment (selection bias) Unclear risk See cell above.
Blinding of participants and personnel
(performance bias)
Pain
Unclear risk Patients and doctors blinded. Blinding
“kept closed until the end of the study”.
Unclear how blinding was achieved
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Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk See cell above.
Blinding of outcome assessment (detection
bias)
Pain
Unclear risk See cell above.
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk See cell above.
Incomplete outcome data (attrition bias)
Pain
Low risk Data appear to be available for all included
patients.
Incomplete outcome data (attrition bias)
Adverse events
Low risk See cell above
Selective reporting (reporting bias) Unclear risk The outcomes are not well-reported.
Other bias Unclear risk It is unclear whether the study is at high
risk of other biases
Were the patients adequately titrated? High risk The patients were not titrated.
For cross-over trials: Are data available for
both time periods?
Unclear risk Not applicable.
Noda 1989
Methods Design: Randomised, parallel group trial
Year: Not reported
Country: Japan
Participants Patients: 30 patients randomised to one of the following groups:
• Placebo (+ buprenorphine SC 8 µg): N = 10, 4 males/6 females; median (range)
age = 51.5 (25 to 72) years; cancer type: renal (2), hepatoma (1), ovarian (1), breast (1),
cervical (1), prostate (1), cholangiocarcinoma (1), maxillary (1), rhabdomyosarcoma
(1); Type of pain: abdominal (6), leg (2), hip (1), chest (1);
• Buprenorphine SC 4 µg: N = 10, 6 males /4 females; median (range) age = 52 (35
to 73) years; cancer type: renal (1), leukaemia (1), gastric (1), breast (1), cervical (1),
rectal (1), cholangiocarcinoma (1), pancreatic (1), tongue (1), sphenoidal tumour (1);
Type of pain: abdominal (4), shoulder (2), hip (1), chest (2), facial (1);
• Buprenorphine IM 0.004 µg + SC 4 µg: N = 10, 6 males /4 females; median
(range) age = 57.5 (20 to 78) years; cancer type: lung (5), tongue (1),
cholangiocarcinoma (1), maxillary (2), pancreatic (1); Type of pain: abdominal (2),
facial (3), chest (5).
Inclusion criteria: “This study was carried out in patients admitted to Kyoto University
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Hospital. Informed verbal consent to participate in this study was obtained from all
patients, but information regarding what and how much drug was to be administered
was not provided to them. Thirty patients included had not undergone any opioid
administration for at least 1 week prior to the study.” “The study was started when the
patients scored their level of pain at VAS 10.”
Exclusion criteria: No information reported.
Interventions Buprenorphine arm (1):
• Drug: Buprenorphine.
• Dose/dosing: “Buprenorphine hydrochloride (0.3 mg/1.5 ml/ampul) was offered
by Ohtsuka Pharm Co. Ltd. It was diluted with 0.9% physiologic saline in proportion
to the body weight of each patient and the rate of drug infusion.” Delivered by a
portable automatic infusion pump at the rate of 4 µg/kg body weight/day. The
butterfly needle was inserted subcutaneously into the patient’s anterior chest wall.
• Formulation: Infusion.
• Route of administration: Subcutanenous.
• Length of treatment: 48 hours.
• Titration schedule: See “Participants” section. No further information provided.
• Rescue medication: See “Dose/dosing” section. No further information provided.
• Other medication: “Patients were prohibited to receive any other analgesics for 6
h before the infusion and during the infusion.”
Buprenorphine arm (2):
• Drug: Buprenorphine.
• Dose/dosing: “Group C received intramuscular administration of buprenorphine
0.004 µg/kg body weight immediately before the start of subcutaneous infusion
delivered by a portable automatic infusion pump at the rate of 4 µg/kg body weight/
day. The butterfly needle was inserted subcutaneously into the patient’s anterior chest
wall.”
• “Buprenorphine hydrochloride (0.3 mg/1.5 ml/ampul) was offered by Ohtsuka
Pharm Co. Ltd. It was diluted with 0.9% physiologic saline in proportion to the body
weight of each patient and the rate of drug infusion.”
• Formulation: IM injection and SC infusion.
• Route of administration: IM and SC.
• Length of treatment: 48 hours.
• Titration schedule: See “Participants” section. No further information provided.
• Rescue medication: See “Dose/dosing” section. No further information provided.
• Other medication: “Patients were prohibited to receive any other analgesics for 6
h before the infusion and during the infusion.”
Placebo:
• Drug: Saline.
• Dose/dosing: Delivered by a portable automatic infusion pump at the rate of 200
µl/h the first day. The butterfly needle was inserted subcutaneously into the patient’s
anterior chest wall.
• Formulation: Infusion.
• Route of administration: Subcunatenous.
• Length of treatment: 6 hours + 48 hours (see “Rescue medication” section below).
• Titration schedule: See “Participants” section. No further information provided.
• Rescue medication: “The patients received supplements, if needed during the first
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day, of indomethacin 50 mg by suppository. The second day, when any patient
complained of intolerable pain [i.e., visual analogue scale (VAS) 10], infusion of
buprenorphine at the rate of 8 µg/kg body weight/day was given. Pain control by this
technique was continued for 48 h.”
• Other medication: “Patients were prohibited to receive any other analgesics for 6
h before the infusion and during the infusion.”
Outcomes • Pain severity: Assessed by patients after the initiation of infusion at 15, 30, and 45
min (Group C only) and 1, 2, 4, 6, 12, 18, 24, 36, 48 h on an 10-cm VAS (0 = no pain
to 10 = worst pain imaginable).
• Side effects: Assessed by nurse questioning.
Notes • Study free of commercial funding? “Buprenorphine hydrochloride (0.3 mg/1.5
ml/ampul) was offered by Ohtsuka Pharm Co. Ltd.” No further information reported.
• Groups comparable at baseline? “There was no significant difference among the
patients in the three groups with regard to age, sex distribution, and body weight. The
baseline values in the VAS were the same (10)”. It is unclear whether the differences in
cancer types and stage between the groups are important.
• ITT analyses undertaken? It is unclear whether analyses were undertaken.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The patients were randomly assigned...”
No further information reported
Allocation concealment (selection bias) Unclear risk See cell above.
Blinding of participants and personnel
(performance bias)
Pain
Unclear risk “Informed verbal consent to participate in
this study was obtained from all patients,
but information regarding what and how
much drug was to be administered was not
provided to them.”No further information
reported
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk See cell above.
Blinding of outcome assessment (detection
bias)
Pain
Unclear risk See cell above.
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk See cell above.
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Incomplete outcome data (attrition bias)
Pain
Unclear risk Three patients failed to complete their as-
signed treatment, and it is unclear if these
patients were included in analysis
Incomplete outcome data (attrition bias)
Adverse events
Unclear risk Three patients failed to complete their as-
signed treatment, and it is unclear if these
patients were included in analysis
Selective reporting (reporting bias) Low risk The expected outcomes are reported.
Other bias Unclear risk It is unclear whether the study is subject to
high risk of other types of bias
Were the patients adequately titrated? High risk The patients were not titrated.
For cross-over trials: Are data available for
both time periods?
Unclear risk NA.
Pace 2007
Methods Design: Randomised, open-label, parallel group trial
Year: Not reported
Country: Italy
Participants Patients: 52 patients randomised and completed the study, randomised to one of the
following groups:
• Buprenorphine group: N = 26, 14 males/12 females; mean age (SD) = 55 (2.6)
years; mean (SD) duration of chronic cancer pain = 1.6 (1.5) years; Type of pain: dull,
profound pain (N = 21), burning, well localised pain (N = 13), tender pain, increased
by movement (N = 10).
• Morphine group: N = 26, 13 males/13 females; mean age (SD) = 54 (3.2) years;
mean (SD) duration of chronic cancer pain = 1.5 (1.8) years; Type of pain: dull,
profound pain (N = 22), burning, well localised pain (N = 13), tender pain, increased
by movement (N = 9).
Inclusion criteria: The outpatients with chronic cancer pain for a period of 1 to 3 years, a
diagnosis of abdominal neoplasia and a pain score equal to at least 40 mm on the visual-
analogue scale (VAS) of Short-Form McGill Pain Questionnaire (SF-MPQ). Patients
with a pain score average equal to at least 4 out of the 11 points on a Likert scale and with
at least 4 observations recorded in the daily diary of pain during the previous week, were
randomised. All the patients taking part in the study had previously received therapy
with NSAIDs or other analgesic agents discontinuously without obtaining successful
results. Eligible patients were confirmed during a week-long screening phase
Exclusion criteria:
1. Presence of acute pain that could confound the evaluation and/or the self-
evaluation of cancer pain;
2. Intake of other experimental drugs within 30 days before the screening;
3. Intake of antiepileptic agents (carbamazepine, phenytoin, sodium valproate,
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phenobarbital);
4. Intake of Tricyclic antidepressants;
5. Patients with creatinine clearance ≤ 60 ml/min (done in order to avoid dose
adjustments/reductions, which would be necessary in patients with impaired renal
function). During the whole study the use of the following drugs was not permitted:
dextrometorphan, opioids, capsaicin, NSAIDs, muscle relaxants, and centrally acting
over-the-counter drugs.
Interventions Buprenorphine arm:
• Drug: Buprenorphine.
• Dose/dosing: 35 µg/h buprenorphine and, in the event of an ineffective control
of pain, the administration of tramadol by oral route was combined to a maximum of
200 mg. The patch was replaced every 72 hours. In case of VAS values > 40, the dose of
buprenorphine was increased to 52.5 µg/h of TD buprenorphine.
• Formulation: TD.
• Route of administration: TD.
• Length of treatment: 8 weeks.
• Titration schedule: See “Participants” section. No further information provided.
• Rescue medication: See “Dose/dosing” section. No further information provided.
• Other medication: See “Participants” section. No further information provided.
Comparison arm:
• Drug: Morphine sulphate.
• Dose/dosing: 60 mg/day of sustained-release morphine sulphate (MT) and
tramadol was administered by oral route to a maximum of 200 mg daily, in case of
need. In case of VAS values > 40, the dose of morphine sulphate was increased to 90
mg daily.
• Formulation: Controlled-release.
• Route of administration: Oral.
• Length of treatment: 8 weeks.
• Titration schedule: See “Participants” section. No further information provided.
• Rescue medication: See “Dose/dosing” section. No further information provided.
• Other medication: See “Participants” section. No further information provided.
Outcomes • Pain severity: Assessed by patients once daily when waking up on an 11-point
Likert scale (0 = no pain to 10 = maximum possible pain). Also assessed at weekly visits
using the SF-MPQ.
• Interence with sleep: Assessed by patients once daily when waking up on an 11-
point Likert scale (0 = no interference to 10 = impossibility to sleep due to pain).
• Patients global impression of change: Assessed by patients at weekly visits on a 7-
point scale, by which patients considered any changes observed from the beginning of
the treatment with an evaluation ranging from “much improved” to “much worsened”.
• Quality of life: Assessed by patients at weekly visits by using the “Profile of Mood
States” (with 6 mood assessments: tension/anxiety, depression/dejection, anger/
aversion, strength/activity, fatigue/inertia and total mood disorder) and the Short
Form-36 Quality of Life (measuring 8 concepts of health: physical activity, limited
activity due to physical problems, social activity, physical pain, general mental health,
limited activity due to emotional problems, vitality and problems of general health).
• Side effects: Patient reported (twice weekly on the telephone?).
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Notes • Study free of commercial funding? No information reported.
• Groups comparable at baseline? Yes, the groups appear to be well-balanced at
baseline.
• ITT analyses undertaken? ITT analyses appear to be undertaken.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The patients eligible for the study were
randomized into blocks of 4, according to
a computer-generated randomized code, to
receive buprenorphine or morphine. Two
groups, matching in age, general baseline
conditions and stagingdegree of abdominal
neoplasia, were formed.”
Allocation concealment (selection bias) Unclear risk See cell above. No further information re-
ported.
Blinding of participants and personnel
(performance bias)
Pain
High risk Open-label study.
Blinding of participants and personnel
(performance bias)
Adverse events
High risk See cell above.
Blinding of outcome assessment (detection
bias)
Pain
High risk See cell above.
Blinding of outcome assessment (detection
bias)
Adverse events
High risk See cell above.
Incomplete outcome data (attrition bias)
Pain
Low risk Data available for all patients.
Incomplete outcome data (attrition bias)
Adverse events
Low risk Data appear to be available for all patients.
Selective reporting (reporting bias) Low risk All obvious outcomes are reported.
Other bias Low risk The study appears to be free of other obvi-
ous biases.
Were the patients adequately titrated? High risk The patients did not appear to be titrated
at all.
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For cross-over trials: Are data available for
both time periods?
Unclear risk NA.
Pasqualucci 1987
Methods Design: Randomised, double-blind, parallel group trial
Year: Not reported
Country: Italy
Participants Patients: 12 patients randomised and completed the study, randomised to one of the
following groups:
• Buprenorphine group: N = 6, 3 males/3 females; mean age (SD) = 61.83 (12.33)
years; Type of cancer: lung (N = 3), rectal (N = 1), uterine (N = 1), pancreatic (N = 1).
• Morphine group: N = 6, 6 males/0 females; mean age (SD) = 67.16 (11.82) years;
mean (SD) duration of chronic cancer pain = 1.5 (1.8) years; Type of cancer: lung (N =
5), rectal (N = 1).
Inclusion criteria: “The patients were recruited from different clinical departments of the
same hospital, and all were suffering from severe continuous, non-incident pain (5 cm
out of a maximum score of 10 on the visual-analogue scale), which did not respond to
common analgesic drugs (non-steroidal anti-inflammatory agents)” “No narcotics had
been administered prior to entry to the trial, and none of the patients had mechanical
and/or neuromuscular disorders of the chest wall.”
Exclusion criteria: None reported.
Interventions Buprenorphine arm:
• Drug: Buprenorphine hydrochloride.
• Dose/dosing: 0.3 mg buprenorphine hydrochloride diluted in 10 ml of 5%
glucose.
• Formulation: Epidural.
• Route of administration: Epidural.
• Length of treatment: Single dose.
• Titration schedule: No titration.
• Rescue medication: See “Dose/dosing” section. No further information provided.
• Other medication: See “Participants” section. No further information provided.
Comparison arm:
• Drug: Morphine hydrochloride.
• Dose/dosing: 3 mg morphine hydrochloride diluted in 10 mL of 5% glucose.
• Formulation: Epidural.
• Route of administration: Epidural.
• Length of treatment: Single dose.
• Titration schedule: No titration.
• Rescue medication: See “Dose/dosing” section. No further information provided.
• Other medication: See “Participants” section. No further information provided.
Outcomes • Pain severity: Assessed by patients immediate before, and 0.5, 1, 2, 3, 4, 5, 6 and
18 hours after drug administration on a visual analogue scale, numerical rating scale
and a simple descriptive scale.
• Adverse events: Any adverse reactions were noted at pain assessments (i.e.,,
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immediate before, and 0.5, 1, 2, 3, 4, 5, 6 and 18 hours after drug administration),
especially the onset, duration and severity of drowsiness, nausea, vomiting , dizziness,
headache, perspiration, urinary retention and itching.
Notes • Study free of commercial funding? No information reported.
• Groups comparable at baseline? Unclear.
• ITT analyses undertaken? ITT analyses appear to be undertaken.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
Pain
Unclear risk Study described as double-blind. Unclear
who is blinded.
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk See cell above.
Blinding of outcome assessment (detection
bias)
Pain
Low risk See cell above. Pain is patient reported.
Probably reasonable to assume that patients
were blinded
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk Study described as double-blind. Unclear
who is blinded and whether this outcome
is assessed by healthcare professionals also
Incomplete outcome data (attrition bias)
Pain
Low risk Data from all participants appear to be
available.
Incomplete outcome data (attrition bias)
Adverse events
Low risk Data from all participants appear to be
available.
Selective reporting (reporting bias) Low risk The main expected outcomes are reported,
although not in a manner that allow their
inclusion in a meta-analysis
Other bias Unclear risk It is unclear whether the study is subject to
other types of bias
Were the patients adequately titrated? High risk The patients were not titrated.
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For cross-over trials: Are data available for
both time periods?
Unclear risk NA.
Poulain 2008
Methods Design: Randomised, double-blind, parallel group trial
Year: February 2004 to January 2005
Country: Austria, Belgium, Croatia, France, Poland, and the Netherlands
Participants Patients: 289 patients were recruited, and of these 92 patients discontinued BUP TDS
treatment and 8 patients died during the run-in phase. The remaining 189 patients (who
responded to BUP TDS treatment) were randomised to one of the following 2 groups:
• Placebo: N = 95, 38 females/56 males, mean(?) age (range) = 63 (39 to 85) years;
53 had metastatic cancer/41 had non-metastatic cancer; concomitant treatment:
corticosteroids (N = 38), benzodiazepines (N = 23), bisphosphonates (N = 13),
tricyclic antidepressants (N = 6), anticonvulsants (N = 6), adjuvant chemotherapy (N =
44), hormonal treatment (N = 21), radiotherapy (N = 15); number of patients
prematurely withdrawn from the study = 24; pain intensity NRS score after the first 12
hours of patch application in the run-in or maintenance phase (SD) = 1.7 (1.4); rescue
medication tablets after the first 12 hours of patch application in the run-in or
maintenance phase (SD) = 0.7 (0.7).
• Buprenorphine: N = 94, 40 females/54 males, mean(?) age (range) = 63 (33 to 83)
years; 72 had metastatic cancer/22 had non-metastatic cancer; concomitant treatment:
corticosteroids (N = 38), benzodiazepines (N = 27), bisphosphonates (N = 8), tricyclic
antidepressants (N = 8), anticonvulsants (N = 7), adjuvant chemotherapy (N = 45),
hormonal treatment (N = 15), radiotherapy (N = 6); number of patients prematurely
withdrawn from the study = 7; pain intensity NRS score after the first 12 hours of
patch application in the run-in or maintenance phase (SD) = 1.5 (1.4); rescue
medication tablets after the first 12 hours of patch application in the run-in or
maintenance phase (SD) = 0.7 (1).
Inclusion criteria: ”Patients with documented malignant disease and insufficient pain re-
lief from their current opioid regimen were eligible. Patients were receiving single opioids
or combination therapy, including oral morphine 90-150 mg/day (n = 105), transdermal
fentanyl 25-50 µg/h (n = 170), tramadol 400-600 mg (n = 75), hydromorphone 8-16
mg (n = 6), or oxycodone 40-60 mg (n = 5). A protocol for chemotherapy or radio-
therapy could be applied concomitantly. Adjuvant analgesics (tricyclic antidepressants,
benzodiazepines, anticonvulsants, muscle relaxants, and corticosteroids) were allowed
providing the dose was stable.“
Exclusion criteria: None reported.
Interventions Buprenorphine arm:
• Drug: Buprenorphine.
• Dose/dosing: 70 µg/h buprenorphine.
• Formulation: TD.
• Route of administration: TD patch.
• Length of treatment: 2 weeks.
• Titration schedule: Eligible patients first entered an open-label, two-week run-in
phase. Previous centrally- and peripherally-acting analgesics were stopped and patients
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were converted to a 70 µg/h BUP TDS patch, applied every three days (Transtec 70
µg/h, Grünenthal). Anticonstipation and antiemetic treatment could be continued,
and/or adjusted. At the end of the run-in phase, patients responding to BUP TDS, that
is, who had a mean pain intensity (PI) of < 5 on a 0-10 scale and a mean intake of ≤ 2
tablets of BUP SL over the last four days, were allocated to BUP TDS or placebo
treatment for a double-blind, two-week maintenance phase.”
• Rescue medication: “Rescue medication (BUP sublingual tablets 0.2 mg,
Temgesic, Schering Plough) was allowed as needed for breakthrough pain during both
phases of the study.”
• Other medication: See “Inclusion criteria” in the cell above.
Comparison arm:
• Drug: Placebo.
Apart from study drug everything else was similar to the buprenorphine arm
Outcomes • Pain (intensity): Assessed by patients twice daily on a 0-10 verbal rating scale (0 =
no pain, 10 = pain as bad as you can imagine).
• Global satisfaction with treatment: Assessed by patients on a 5-point scale
(excellent, very good, good, fair, poor).
• Adverse events: Patients asked by investigator at each visit.
• Responding patients defined as “those who had a mean PI of < 5 during the last
six days of the maintenance phase and a mean daily BUP SL intake of ≤ 2 tablets over
the entire maintenance phase”.
Notes • Study free of commercial funding? “This study was sponsored by Grünenthal
GmbH, Germany.”
• Groups comparable at baseline? The baseline characteristics of the groups appear
to be comparable although more patients in the buprenorphine group have metastatic
cancer relative to the placebo group. However, the pain intensity NRS scores and
rescue medication tablet consumption after 12 hours of patch application in the run-in
or maintenance phase are similar between the groups.
• ITT analyses undertaken? The analyses appear to be ITT. The safety analyses
included all 189 patients and the efficacy analyses included 188/189 patients. One
patient in the placebo group was excluded from the efficacy analyses due to missing
data (no pain assessment).
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomization was performed in blocks
with a 1:1 ratio (BUP TDS: placebo).” No
more information reported
Allocation concealment (selection bias) Unclear risk Not enough information is reported to as-
sess whether there was allocation conceal-
ment
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Blinding of participants and personnel
(performance bias)
Pain
Low risk “Hospital pharmacies received coded study
medication from the sponsor and delivered
the blinded supply for each patient. BUP
TDS and placebo patches were identical
in appearance and adhesive properties. The
randomization list was stored in a sealed,
nontransparent envelope and the code was
not broken until the database had been
locked.”
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk See cell above.
Blinding of outcome assessment (detection
bias)
Pain
Low risk See cell above.
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk Patient-reported. See cell above.
Incomplete outcome data (attrition bias)
Pain
Low risk The safety analyses included all 189 pa-
tients and the efficacy analyses included
188/189 patients. One patient in the
placebo group was excluded from the effi-
cacy analyses due to missing data (no pain
assessment)
Incomplete outcome data (attrition bias)
Adverse events
Low risk See cell above.
Selective reporting (reporting bias) Low risk The expected outcomes are reported.
Other bias Unclear risk It is unclear whether the study results are
subject to high risk of other bias(es)
Were the patients adequately titrated? Low risk Yes, it appears so.
For cross-over trials: Are data available for
both time periods?
Unclear risk NA.
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Methods Design: Randomised, single/double(?)-blind, cross-over trial
Year: Not reported
Country: France
Participants Patients: 10 patients, males and females (no numbers given) aged 18 to 60 years, hos-
pitalised with severe disabling pain from advanced cancer who were lucid and able to
communicate with the investigator, and who received insufficient pain relief from non-
opioid analgesics
Inclusion criteria: See above. No further information reported.
Exclusion criteria: Pregnant women, patients already receiving high doses of opiates, and,
it seems, those with addiction problems, intolerance to morphine or buprenorphine or
both (?), asthma, cerebral pathology, and hepatic and renal impairment
Interventions Buprenorphine arm:
• Drug: Buprenorphine.
• Dose/dosing: 1 mL ampoule of 0.3 mg buprenorphine at 7.00 o’clock. “Injection
of both drugs was maintained for at least 9 hours, the time of the experiment.
Thereafter, and as required by the patient, a reinjection of the ongoing drug, [or?] an
injection of the patient’s usual analgesic could be administered.” That is, any additional
analgesics were not administered until at least 16.00 o’clock.
• Formulation: IM injection.
• Route of administration: IM injection.
• Length of treatment: 8 days with 4 days of buprenorphine treatment and 4 days
of morphine treatment.
• Titration schedule: No information reported.
• Rescue medication: See “Dose/dosing” above.
• Other medication: See “Dose/dosing” above.
Comparison arm:
• Drug: Morphine.
• Dose/dosing: 2 mL ampoule of 10 mg morphine at 7.00 o’clock. “Injection of
both drugs was maintained for at least 9 hours, the time of the experiment. Thereafter,
and as required by the patient, a reinjection of the ongoing drug, [or?] an injection of
the patient’s usual analgesic could be administered.” That is, any additional analgesics
were not administered until at least 16.00 o’clock.
• Formulation: IM injection.
• Route of administration: IM injection.
• Length of treatment: 8 days with 4 days of buprenorphine treatment and 4 days
of morphine treatment.
• Titration schedule: No information reported.
• Rescue medication: See “Dose/dosing” above.
• Other medication: See “Dose/dosing” above.
• For cross-over trials: Cross-over schedule: “The patient is his own control since he/
she received the two drugs within eight days: The drugs will each be administered for 4
days, the day of injection being determined in advance using the permutation table of
Hazard.” No further information reported.
Outcomes Patients were interviewed just before taking the drug (time 0) and every hour for the
first 5 hours and then again at hour 9 by a single observer qualified to detect potential
side effects and evaluate the intensity of pain, which was measured on a 4-point verbal
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rating scale (0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe, intense pain)
Notes • Study free of commercial funding? Unclear. No information reported.
• Groups comparable at baseline? Unclear. No information reported.
• ITT analyses undertaken? The efficacy analyses may be conducted as ITT
analyses, but it is not clearly evident due to very limited reporting of the data.
This studywas published inFrench and lay translated byMSHwith input fromDrValeria
Martinez MD PhD, Praticien Hospitalier, Anesthésiste-Algologue, Groupe Hospitalier
Raymond Poincaré, 104, Bd Raymond Poincaré, 92380 Garches France, regarding the
nature of the “permutation table of Hazard” referred to in the publication
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The patient is his own control since he/she
received the two drugs within eight days:
The drugs will each be administered for 4
days, the day of injection being determined
in advance using the permutation table of
Hazard.” No further information reported
Allocation concealment (selection bias) Unclear risk See cell above.
Blinding of participants and personnel
(performance bias)
Pain
Unclear risk The study is described as single-blind (pa-
tient blinded), but also reported that al-
though the drugs have not been condi-
tioned anonymously, the person adminis-
tering the injection is not the same as the
interviewer asking about the reported out-
comes. The personnel providing care (e.g.,
injection) is therefore not blinded
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk Outcome not reported.
Blinding of outcome assessment (detection
bias)
Pain
Low risk Patient and interviewer blinded. See also
cell above.
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk Outcome not reported.
Incomplete outcome data (attrition bias)
Pain
Low risk All data appear to be included in the anal-
yses.
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Incomplete outcome data (attrition bias)
Adverse events
Unclear risk Outcome not reported.
Selective reporting (reporting bias) High risk It appears that adverse event data were col-
lected, but not reported
Other bias Unclear risk It is unclear whether the study was subject
to high risk of other types of bias
Were the patients adequately titrated? High risk No information reported about titration,
but unlikely as the dose is set
For cross-over trials: Are data available for
both time periods?
Low risk Efficacy data are available from both time
periods.
Sarhan 2009
Methods Design: Randomised, parallel-group trial
Year: Not reported
Country: Egypt
Participants Patients: “32 opioid naive patients suffering from chronic cancer pain with visual ana-
logue scale (VAS) 7 were randomly allocated to one of two groups 16 patients each”.
No further information reported
Inclusion criteria: See above. No further information reported.
Exclusion criteria: See above. No further information reported.
Interventions Buprenorphine arm:
• Drug: Buprenorphine.
• Dose/dosing: Patches every 3 days starting with “doses of 35 µg/h which was
increased to 52.5 µg/h patch and gradually to 70 µg/h for VAS 3.”
• Formulation: TD patch.
• Route of administration: TD.
• Length of treatment: 6 weeks.
• Titration schedule: No information reported.
• Rescue medication: See “Dose/dosing” above. The outcomes measured (see
below) suggests that diclofenac sodium was allowed.
• Other medication: No information reported.
Comparison arm:
• Drug: Fentanyl.
• Dose/dosing: Patches every 3 days starting with “doses of 25 µg/h which was
increased to 50 µg/h patch and gradually to 75 µg/h for VAS 3.”
• Formulation: TD patch.
• Route of administration: TD.
• Length of treatment: 6 weeks.
• Titration schedule: No information reported.
• Rescue medication: See “Dose/dosing” above. The outcomes measured (see
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below) suggests that diclofenac sodium was allowed.
• Other medication: No information reported.
Outcomes “Measurements: were done for 6 weeks by an assessor blinded to the study *severity
of pain by VAS every 3 days *Mean number of each category patch dose *treatment
satisfaction scale *Mean daily dose of diclofenac sodium *Mean cost of treatment *Side
effects and complications.”
Notes • Study free of commercial funding? Unclear. No information reported.
• Groups comparable at baseline? Unclear. No information reported.
• ITT analyses undertaken? Unclear. No information reported.
This study was published as an abstract only. We contacted the trial author via email on
19 September 2014 for study details and data
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Group assignment described as random.
No further information reported
Allocation concealment (selection bias) Unclear risk See cell above.
Blinding of participants and personnel
(performance bias)
Pain
Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk See cell above.
Blinding of outcome assessment (detection
bias)
Pain
Unclear risk Assessor described as blinded, but no fur-
ther information reported, and unclear if
this outcome was patient reported
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk See cell above.
Incomplete outcome data (attrition bias)
Pain
Unclear risk No actual data presented. Data just de-
scribed as being statistically significantly
different or not
Incomplete outcome data (attrition bias)
Adverse events
Unclear risk See cell above.
Selective reporting (reporting bias) Unclear risk See cell above.
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Other bias Unclear risk It is unclear if the study is subject to high
risk of other biases
Were the patients adequately titrated? Unclear risk No information reported.
For cross-over trials: Are data available for
both time periods?
Unclear risk NA.
Sittl 2003
Methods Design: Randomised, double-blind, parallel group trial
Year: Not reported
Country: Austria, Germany, and the Netherlands
Participants Patients: 157 patients were enrolled and randomised to one of the following 4 groups:
• Placebo: N = 38, 21 females/17 males, mean age (SD) = 58.3 (13.3) years; 29 had
malignant pain origin/9 had non-malignant pain origin; prior opioid analgesic therapy:
tramadol (N = 26), buprenorphine (N = 7), codeine (N = 6), morphine (N = 3),
piritramide (N = 2), tilidine (N = 2); number of patients prematurely withdrawn from
the study = 16.
• Buprenorphine 35 µg/h: N = 41, 20 females/21 males, mean age (SD) = 57.4
(10.3) years; 32 had malignant pain origin/9 had non-malignant pain origin; prior
opioid analgesic therapy: tramadol (N = 18), buprenorphine (N = 6), codeine (N = 6),
morphine (N = 6), piritramide (N = 0), tilidine (N = 2); number of patients
prematurely withdrawn from the study = 12.
• Buprenorphine 52.5 µg/h: N = 41, 23 females/18 males, mean age (SD) = 63.7
(11.3) years; 31 had malignant pain origin/10 had non-malignant pain origin; prior
opioid analgesic therapy: tramadol (N = 24), buprenorphine (N = 5), codeine (N = 2),
morphine (N = 6), piritramide (N = 3), tilidine (N = 3); number of patients
prematurely withdrawn from the study = 11.
• Buprenorphine 70 µg/h: N = 37, 22 females/15 males, mean age (SD) = 54.9
(12.5) years; 29 had malignant pain origin/8 had non-malignant pain origin; prior
opioid analgesic therapy: tramadol (N = 18), buprenorphine (N = 9), codeine (N = 4),
morphine (N = 3), piritramide (N = 1), tilidine (N = 4); number of patients
prematurely withdrawn from the study = 5.
Inclusion criteria: “Patients aged ≥18 years with chronic, severe pain related to cancer
or other diseases
were enrolled in the study.”
Exclusion criteria: “Women using inadequate contraceptive measures or who were preg-
nant, possibly pregnant, or lactating were excluded from the study, as were patients with
elevated intracranial pressure, a history of abuse of centrally acting substances or cerebral
convulsions, previous extensive dermal damage in the patch area, or clinically relevant
impairment of respiratory function. Patients with known hypersensitivity to opioids,
impaired hepatic or renal function, or impaired consciousness, or who were receiving
treatment with monoamine oxidase inhibitors also were excluded.”
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Interventions Buprenorphine arms (3):
• Drug: Buprenorphine.
• Dose/dosing: 35 µg/h or 52.5 µg/h or 70 µg/h buprenorphine administered in
up to 5 patches applied consecutively for 72 hours each to the subclavicular chest or
upper back region of each patient.
• Formulation: TD.
• Route of administration: TD patch.
• Length of treatment: Up to 15 days.
• Titration schedule: “Patients were switched directly from their previous analgesic
medications on day 1 of the study”
• Rescue medication: “Sublingual buprenorphine tablets (0.2 mg) were permitted
throughout the study as rescue analgesic medication to ensure that patients achieved
adequate pain control at all times.”
• Other medication: “On day 1 of the study, patients also were allowed to continue
taking their prestudy analgesic medications if necessary. This measure was taken to
avoid any gaps in analgesia because of the pharmacokinetic characteristics of
buprenorphine TDS. From day 2 onward, patients were not permitted to take any
centrally acting analgesic other than the study medication.”
Comparison arm:
• Drug: Placebo
Apart from study drug everything else was similar to the buprenorphine arms
Outcomes • Pain intensity: Assessed by patients twice daily on a 5-point verbal rating scale (0
= none, 1 = slight, 2 = moderate, 3 = severe, 4 = very severe).
• Pain relief: Assessed by patients on days 2 and 3, at each patch change (every 3
days) and at study end on a 4-point verbal rating scale. “Degree of pain relief was
categorized as poor, satisfactory, good or complete.”
• Duration of sleep uninterrupted by pain the previous night: Assessed by patients
on a 4-point verbal rating scale with the following categories: > 6, 3 to 6, 2 to 3, or < 2
hours.
• Responding patients defined as “any patient who required no more than 1
sublingual tablet of buprenorphine as rescue medication per day from day 2 until the
end of the study and who recorded at least satisfactory pain relief at each application of
a new patch. Patients withdrawing prematurely from the study because of poor
tolerability or inadequate pain relief were considered nonresponders”.
• Adverse events: Systemic AE recorded throughout the trial, patch-related AE
assessed at patch change (including swelling, erythema, pruritus, signs of infection,
other dermal damage).
Notes • Study free of commercial funding? “This study was supported by Grunenthal
GmbH, Aachen, Germany.”
• Groups comparable at baseline? “There were no significant differences at baseline
between treatment groups in demographic parameters, although patients in the
buprenorphine 52.5 µg/ group were older than those in the other treatment groups (p
< 0.05)”.
• ITT analyses undertaken? The ITT analyses included 154/157 patients.
Risk of bias Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported.
Allocation concealment (selection bias) Unclear risk See cell above.
Blinding of participants and personnel
(performance bias)
Pain
Unclear risk Study described as double-blind, and al-
though it does not detail who was blinded
and how blinding was employed, the pa-
tient is likely to be among those who
were blinded, but unclear whether treating
healthcare professionals were blinded
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk See cell above.
Blinding of outcome assessment (detection
bias)
Pain
Low risk Patient-reported. Study described as dou-
ble-blind, and although it does not detail
whowas blinded andhowblindingwas em-
ployed, the patient is likely to be among
those who were blinded
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk Investigator who recording this outcome
was blinded to the study/treatment group
Incomplete outcome data (attrition bias)
Pain
Low risk The analyses include 154/157 patients.
Incomplete outcome data (attrition bias)
Adverse events
Low risk The analyses include 154/157 patients.
Selective reporting (reporting bias) Low risk All obvious outcomes appear to be re-
ported.
Other bias Low risk No other obvious biases were observed.
Were the patients adequately titrated? Low risk The patients were not titrated, but had ac-
cess to top-up fast-acting strong analgesia
to ensure adequate pain control
For cross-over trials: Are data available for
both time periods?
Unclear risk NA.
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Methods Design: Randomised, double-blind, parallel group trial
Year: Not reported
Country: Germany and Poland
Participants Patients: 174 patients entered the run-in phase, of these 37 were excluded and 137
patients were randomised to one of the following 2 groups:
• Placebo: N = 47, 24 females/23 males, mean age (SD) = 55.7 (12.9) years; 19 had
malignant pain origin/28 had non-malignant pain origin; cancer sites: Duodenum/
colon/rectum (N = 5), uterus/ovary/vulva (N = 2), breast (N = 2), mouth/tongue/
larynx (N = 2), bronchus/lung/pleura (N = 3), oesophagus/stomach (N = 0), prostate/
kidney/bladder (N = 2), liver/gallbladder/pancreas (N = 3), other (N = 0), secondary
metastases (N = 9).
• Buprenorphine 35 µg/h: N = 90, 43 females/47 males, mean age (SD) = 56 (12.
1) years; 26 had malignant pain origin/64 had non-malignant pain origin; cancer sites:
duodenum/colon/rectum (N = 6), uterus/ovary/vulva (N = 4), breast (N = 3), mouth/
tongue/larynx (N = 3), bronchus/lung/pleura (N = 2), oesophagus/stomach (N = 2),
prostate/kidney/bladder (N = 2), liver/gallbladder/pancreas (N = 1), other (N = 3),
secondary metastases (N = 9).
Inclusion criteria: ”Eligible patients were aged ≥18 years and were receiving outpatient
or inpatient hospital care for severe or very severe chronic pain related to cancer or other
disorders justifying treatment with strong opioids such as buprenorphine. The probable
course of the patient’s disease and pain could not be such that they might interfere with
adherence to the study protocol, and no surgery could be scheduled during the study
period.“ ”The principal criterion for inclusion in the double-blind phase was that pain
had been at least satisfactorily relieved during the run-in phase.“
Exclusion criteria: ”Exclusion criteria were pregnancy or lactation; abuse of alcohol, hyp-
notics, analgesics, psychotropic drugs, or other central nervous system-acting substances;
hypersensitivity to opioids; a history of convulsions; compromised respiratory function;
elevated intracranial pressure; and previous extensive damage to the site where the patch
was to be applied. Patients receiving concomitant opioids apart from buprenorphine
SL or monoamine oxidase inhibitors in the 2 weeks before study enrollment were also
excluded.“
Interventions Buprenorphine arms:
• Drug: Buprenorphine.
• Dose/dosing: 35 µg/h buprenorphine administered in 3 patches applied
consecutively for 72 hours each. ”With TDSs, there is a time lag before the
achievement of effective serum drug concentrations. Therefore, the period during
which the first patch was applied (days 7-9) was considered an influx phase and the
usual dose of buprenorphine SL taken during the run-in phase was also taken on the
first day on which the first patch was applied (day 7) to avoid analgesic gaps.“
• Formulation: TD.
• Route of administration: TD patch.
• Length of treatment: 9 days (i.e., study days 7 to 15; study days 1 to 6 were the
run-in phase, study days 7 to 9 were influx, and study days 10 to 15 comprised the
double-blind phase).
• Titration schedule: ”The study began with a 6-day run-in phase during which
patients received buprenorphine SL 0.2-mg tablets as needed (range, 0.8-1.6 mg/d
[corresponding to 4-8 tablets/d])....The principal criterion for inclusion in the double-
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blind phase was that pain had been at least satisfactorily relieved during the run-in
phase.“
• Rescue medication: ”Patients in both treatment arms were permitted to use rescue
buprenorphine SL 0.2-mg tablets as needed throughout the double-blind phase to
ensure adequate analgesia.“
• Other medication: It seems that opioids other than the study medication were
prohibited, while other concomitant medications were permitted.
Comparison arm:
• Drug: Placebo
Apart from study drug everything else was similar to the buprenorphine arm
Outcomes • Pain intensity: Assessed by patients 3 times daily (morning, afternoon, evening)
on days 6, 9, and 15 on a 5-point verbal rating scale (1 = no pain, 2 = mild pain, 3 =
moderate pain, 4 severe pain, 5 = very severe).
• Pain relief: Assessed by patients on days 7, 10 and 16 on a 4-point verbal rating
scale (unsatisfactory, satisfactory, good or complete).
• Duration of sleep uninterrupted by pain the previous night: Assessed by patients
in the morning on a 4-point verbal rating scale with the following categories: > 6, 3 to
6, 2 to 3, or < 2 hours.
• Adverse events: recorded throughout the trial.
Notes • Study free of commercial funding? ”This study was sponsored by Grunenthal
GmbH, Aachen, Germany.“
• Groups comparable at baseline? ”Cancer patients in the placebo group had more
advanced disease with regard to metastases; half had secondary tumours, compared
with approximately one third of cancer patients in the buprenorphine TDS group.“
• ITT analyses undertaken? The analyses appear to be conducted as ITT.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was conducted in a 2:1
ratio (buprenorphine TDS:placebo) using
permuted block randomisation, with a sin-
gle block generated according to the urn
model. The size of the blocks was pro-
vided in the randomisation list and was
not imparted to investigators. The as-
signed patient numbers were documented
on all pages of the case-report form. Af-
ter the randomisation criteria had been
checked within each centre, eligible pa-
tients were randomised to receive 3 sequen-
tial patches containing buprenorphine 35
µg/h or placebo
Allocation concealment (selection bias) Unclear risk See cell above. No further information re-
ported.
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Blinding of participants and personnel
(performance bias)
Pain
Unclear risk The study is described as double-blind, but
does not detail how blinding was accom-
plished and who were blinded
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk See cell above.
Blinding of outcome assessment (detection
bias)
Pain
Low risk Although the study is described as double-
blind, but does not detail how blinding was
accomplished and who were blinded, the
patient was probably blinded
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk Unclear who was blinded and whether this
outcome was patient-reported. See also cell
above
Incomplete outcome data (attrition bias)
Pain
Low risk ”all patients who entered the double-blind
phasewere included in the analyses (includ-
ing premature withdrawals)
Incomplete outcome data (attrition bias)
Adverse events
Low risk See cell above.
Selective reporting (reporting bias) Low risk All obvious outcomes appear to be re-
ported, although not by pain subgroup
(cancer/non-cancer), which would allow
their inclusion into the results section
Other bias Low risk No other obvious biases were observed.
Were the patients adequately titrated? Low risk The patients were probably adequately
titrated.
For cross-over trials: Are data available for
both time periods?
Unclear risk NA.
Wang 2012
Methods Design: Randomised, double-blind, parallel group trial
Year: 2005 to 2010
Country: China
Participants Patients: 163 patients were screened, of these 43 did not meet the inclusion criteria
(declined participation, N = 14; adjuvant chemotherapy, N = 11; elevated levels of serum
transaminase N = 9; respiratory tract infection, N = 9) while the remaining 120 patients
were randomised to one of the following 2 groups (each consisting of two sub-groups
based on the status of P-gp expression in their tumour tissues):
71Buprenorphine for treating cancer pain (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wang 2012 (Continued)
Buprenorphine:
• B1 [P-gp+ tumours, defined as specimens with ≥ 10% of positively staining
cells]: N = 30, 8 females/22 males, mean age (SD) = 57.4 (10.2) years; cancer type:
Oesophageal (N = 8), cardia (N = 3), breast (N = 5), lung (N = 7), colon (N = 3),
rectum (N = 4).
• B2 [P-gp- tumours, defined as specimens with < 10% of positively staining cells]:
N = 30, 9 females/21 males, mean age (SD) = 57.5 (9.7) years; cancer type:
Oesophageal (N = 8), cardia (N = 3), breast (N = 4), lung (N = 7), colon (N = 4),
rectum (N = 4).
Morphine:
• M1 [P-gp+ tumours, defined as specimens with ≥ 10% of positively staining
cells]: N = 30, 9 females/21 males, mean age (SD) = 57.5 (10.4) years; cancer type:
Oesophageal (N = 6), cardia (N = 5), breast (N = 4), lung (N = 7), colon (N = 4),
rectum (N = 4).
• M2 [P-gp- tumours, defined as specimens with < 10% of positively staining cells]:
N = 30, 10 females/20 males, mean age (SD) = 57.2 (11.1) years; cancer type:
Oesophageal (N = 7), cardia (N = 4), breast (N = 5), lung (N = 7), colon (N = 3),
rectum (N = 4).
Inclusion criteria: ”Individual patients with histologically confirmed malignant tumours
at stage IV, able to communicate effectively with the healthcare providers, regardless of
previous chemotherapy and surgical treatment, were included.“
Exclusion criteria: ”individual tumor patients with opioid intolerance, previous usage of
strong opioids, severe renal or hepatic dysfunction, predominantly neuropathic pain, or
breakthrough pain; or individuals who needed neural block or neuroablative treatment
for pain relief, with impaired sensory or cognitive function, with coma or other mental
disorders were excluded.“
Interventions Buprenorphine arm (B1 and B2):
• Drug: Buprenorphine.
• Dose/dosing: ”All patients with pain due to surgery, tumor progression, or
metastases were initially treated orally with 0.05 g of diclofenac sodium suppositories
(Jiangsu Yuan Heng Pharmaceutical Company, Nanjing, China) every 8-12 h, 0.1 g of
sustained-releasing tramadol hydrochloride (Beijing Adorable Pedicle Pharmaceutical
Company, Beijing, China), or 0.03 g of sustained-releasing morphine hydrochloride
(Southwest Pharmaceutical Company, Chongqing, China every 12 h. Individual
patients, who still suffered with unsustainable pain, received a patient-controlled
intravenous analgesia (PCIA) pump (Dragon Medical Device, Zhangjiagang, China).“
”the B1 and B2 groups of patients were treated with a load dose of 0.00015 g BNP“
[buprenorphine]. Subsequently, ”The B1 and B2 groups of patients were treated with
0.000025 g x kg−2 BNP and 0.01 g azasetron in 100 ml of saline“ with consistent
transfusions of 2 ml per h, self-adjusted with 0.5 ml of PCA solution and a lock time of
20 min.
• Formulation: Intravenous.
• Route of administration: Intravenous.
• Length of treatment: Actual study-drug treatment length appears to be 36 hours.
• Titration schedule: See ”Dose/dosing“ above.
• Rescue medication: See ”Dose/dosing“ above.
• Other medication: See ”Dose/dosing“ above. No further information reported.
Morphine arm (M1 and M2):
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• Drug: Morphine.
• Dose/dosing: ”All patients with pain due to surgery, tumor progression, or
metastases were initially treated orally with 0.05 g of diclofenac sodium suppositories
(Jiangsu Yuan Heng Pharmaceutical Company, Nanjing, China) every 8-12 h, 0.1 g of
sustained-releasing tramadol hydrochloride (Beijing Adorable Pedicle Pharmaceutical
Company, Beijing, China), or 0.03 g of sustained-releasing morphine hydrochloride
(Southwest Pharmaceutical Company, Chongqing, China every 12 h. Individual
patients, who still suffered with unsustainable pain, received a patient-controlled
intravenous analgesia (PCIA) pump (Dragon Medical Device, Zhangjiagang, China).“
”The M1 and M2 groups of patients received a load dose of 0.0025 g morphine“.
”Subsequently, the patients in the M1 and M2 groups were provided with the PCIA
solution containing 0.00075 g x kg−2 morphine and 0.01 g azasetron in 100 ml of
saline with consistent transfusions of 2 ml per h, self-adjusted with 0.5 ml of PCA
solution and a lock time of 20 min.“ One week later, due to poor responses, the M1
group of patients received 0.0011 g x kg−2 morphine and 0.01 mg azasetron using the
same treatment condition.”
• Formulation: Intravenous.
• Route of administration: Intravenous.
• Length of treatment: Actual study-drug treatment length appears to be 36 hours.
• Titration schedule: See “Dose/dosing” above.
• Rescue medication: See “Dose/dosing” above.
• Other medication: See “Dose/dosing” above. No further information reported.
Outcomes • Pain intensity: Assessed by patients at baseline (before treatment), 4 h, 12 h, 24 h
and 36 h “using VAS: 0 (no pain feeling and highly satisfactory); 1-2 (satisfactory), 3-5
(primary satisfactory), 6-7 (primary unsatisfactory), 8-9 (unsatisfactory), and 10
(utmost pain and highly unsatisfactory).”
Notes • Study free of commercial funding? No information reported.
• Groups comparable at baseline? The baseline characteristics of the four groups
were comparable in terms of age, gender, weight, cancer type, baseline VAS and
education.
• ITT analyses undertaken? Unclear. Not enough information reported.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No information is reported about the ran-
dom sequence generation, but 120 patients
were randomised into 4 groups with strat-
ification for tumour type, P-gp expres-
sion, and their demographic characteristics,
which (due to the relatively large number
of stratification factors) increases the risk
that the allocation ceases to be random
Allocation concealment (selection bias) High risk See above.
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Blinding of participants and personnel
(performance bias)
Pain
Unclear risk The study reports that the analgesics effect
was tested in “a double blinded manner”,
but reports no further details
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk Outcome not reported.
Blinding of outcome assessment (detection
bias)
Pain
Unclear risk The study reports that the analgesics effect
was tested in “a double blinded manner”,
but reports no further details
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk Outcome not reported.
Incomplete outcome data (attrition bias)
Pain
Unclear risk It is unclear if data are included from all the
patients at all the time points
Incomplete outcome data (attrition bias)
Adverse events
Unclear risk Outcome not reported.
Selective reporting (reporting bias) High risk Adverse events not reported.
Other bias Unclear risk It is unclear whether the study is subject to
high risk of other bias(es)
Were the patients adequately titrated? Unclear risk It is unclear, based on the reported informa-
tion, whether the patients were adequately
titrated
For cross-over trials: Are data available for
both time periods?
Unclear risk NA.
Yajnik 1992
Methods Design: Randomised, double-blind, parallel group trial
Year: 1988 to 1989
Country: India
Participants Patients: 75 patients (aged 20 to 30 years: N = 6; 31 to 40 years: N = 7; 41 to 50 years:
N = 29; 51 to 60 years: N = 21; ≥ 61 years: N = 12; only given overall, not per group)
randomised to one of the following 3 groups:
• Buprenorphine: N = 25, 10 females/15 males; cancer type: Stomach (N = 3), liver
(N = 1), gallbladder (N = 1), breast (N = 6), oral (N = 5), penis (N = 2), thyroid (N =
1), bladder (N = 1), prostate (N = 2), rectum (N = 3).
• Buprenorphine + phenytoin: N = 25, 11 females/14 males; cancer type: Stomach
(N = 3), liver (N = 2), pancreas (N = 1), breast (N = 6), oral (N = 4), penis (N = 2),
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ovarian (N = 1), bladder (N = 2), prostate (N = 2), rectum (N = 2).
• Phenytoin: N = 25, 11 females/14 males; cancer type: Stomach (N = 3),
oesophageal (N = 2), liver (N = 1), gallbladder (N = 1), breast (N = 5), oral (N = 5),
penis (N = 2), ovarian (N = 1), bladder (N = 2), prostate (N = 1), rectum (N = 2).
Inclusion criteria: “In this study, 75 patients with complaints of malignant pain were
assigned at random to 1 of 3 treatment groups, phenytoin (PHT) alone, buprenorphine
(Bu) alone, or buprenorphine plus phenytoin, from August 1988 to March 1989. Ap-
proximately 9 patients were admitted to the study per month. The patients in this trial
had all been treated with surgery and/or radiotherapy, but none had any type of pain
therapy. All had moderate-to-severe pain levels as determined by use of a visual analogue
scale (see below). They were taking no drugs other than those used during the study.
” Only patients with pain scores of 6 to 10 cm on a 10-cm VAS (i.e., moderate-severe
pain) and requesting pain medication were included
Exclusion criteria: None reported.
Interventions Buprenorphine arm:
• Drug: Buprenorphine.
• Dose/dosing: 0.2 mg twice daily.
• Formulation: SL.
• Route of administration: SL.
• Length of treatment: 1 month.
• Titration schedule: No information reported.
• Rescue medication: No information reported.
• Other medication: See “Inclusion criteria” in cell above. No further information
reported.
Buprenorphine + phenytoin arm:
• Drug: Buprenorphine + phenytoin.
• Dose/dosing: 0.1 mg twice daily buprenorphine, 50 mg twice daily phenytoin.
• Formulation: SL buprenorphine, oral phenytoin.
• Route of administration: SL, oral.
• Length of treatment: 1 month.
• Titration schedule: No information reported.
• Rescue medication: No information reported.
• Other medication: See “Inclusion criteria” in cell above. No further information
reported.
Phenytoin arm:
• Drug: Phenytoin.
• Dose/dosing: 100 mg twice daily.
• Formulation: Oral.
• Route of administration: Oral.
• Length of treatment: 1 month.
• Titration schedule: No information reported.
• Rescue medication: No information reported.
• Other medication: See “Inclusion criteria” in cell above. No further information
reported.
Outcomes • Pain intensity: Assessed by patients at baseline (before treatment) using a 10-cm
VAS (0 = no pain, 10 = worst possible pain.
• Pain relief: Assessed by patients post-treatment twice daily (4 hours after a drug
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dose) for the first 7 days and then weekly for the remaining 3 weeks using the fraction-
of-rupee (paired) technique. The patients’ assessment of pain relief was quantified as
follows (rupee scale = 1 to 100 paise): None = pain relief < 25 paise; poor = pain relief
between 25 and 50 paise; moderate = pain relief between 50 and 75 paise; good = pain
relief between 75 and 100 paise.
• Side effects: Recorded every 8 hours during the first 72 hours, and possibly longer.
Notes Study free of commercial funding? No information reported.
Groups comparable at baseline? The baseline characteristics of the three groups were
comparable in terms of gender and cancer type. Otherwise not reported
ITT analyses undertaken? Unclear. Not enough information reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported.
Allocation concealment (selection bias) Unclear risk See cell above.
Blinding of participants and personnel
(performance bias)
Pain
Unclear risk “Both the patient and observer were blind
to their treatment”, but no further infor-
mation reported
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk See cell above.
Blinding of outcome assessment (detection
bias)
Pain
Unclear risk See cell above.
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk See cell above.
Incomplete outcome data (attrition bias)
Pain
Low risk Data from all the patients are included.
Incomplete outcome data (attrition bias)
Adverse events
Low risk It appears that data from all the patients are
included.
Selective reporting (reporting bias) Low risk The main expected outcomes are reported.
Other bias Unclear risk It is unclear whether the study is subject to
high risk of other bias(es)
Were the patients adequately titrated? Unclear risk No information is reported.
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For cross-over trials: Are data available for
both time periods?
Unclear risk NA.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Corli 1988 Comparison not in PICO: Buprenorphine versus buprenorphine + diclofenac
Deng 2002 No cancer patients received buprenorphine.
Likar 2006 Not a RCT.
Likar 2007 Mixed population, only 9/49 patients had cancer. Results not presented separately for cancer patients
Taguchi 1982 Not a RCT.
Wirz 2009 Not randomised allocation to treatment. Patients randomly selected from pools of patients already undergoing
treatments under investigation instead
Characteristics of studies awaiting assessment [ordered by study ID]
Lari 1985
Methods “Epidural buprenorphine versus morphine in the bone cancer pain”
Participants “With regard to the drugs used, patients were divided (Fig. 1) into two groups, sufficiently homogeneous for number,
age, sex, and topography of the neoplastic lesion, treated with morphine and buprenorphine at doses respectively of
0.07 mg/kg and 4 mcg/kg every 12 hours.” (Google translate on 24 July 2014)
Interventions See cell above.
Outcomes Pain intensity, side effects.
Notes The study is published in Italian and translation of the article has revealed no mention about allocation to treatment
beyond the description of the study outlined in the “Participants” section 3 cells above. It is thus uncertain whether
it was a randomised controlled trial
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Methods Open-label, multicentre study of safety, pharmacokinetics and efficacy of buprenorphine TD system (BTDS) in
children from seven to 16 years, inclusive, who require continuous opioid analgesia for moderate to severe pain
Participants Inclusion criteria:
• Male and female patients, 7 to 16 years of age, inclusive, with malignant or nonmalignant, or both, moderate
to severe pain requiring or anticipated to require continuous, around-the-clock, opioid treatment for at least 2
weeks (based on the investigator’s judgment).
• Patients must have written informed consent provided by the parent or legal guardian and assent provided by
the patient, when appropriate.
• Patients on incoming opioids must be taking ≤ 80 mg morphine or equivalent if aged 12 to 16 years or ≤ 40
mg morphine or equivalent if aged 7 to 11 years prior to initiation with BTDS treatment.
• Patients must be able to understand and complete the age appropriate scale to rate pain intensity, i.e., patients
must not have a cognitive developmental delay or any other condition that would preclude them from completing
age appropriate pain scale.
• Patients with malignant and/or nonmalignant medical conditions causing moderate to severe pain requiring
continuous, around-the-clock opioid analgesic therapy such as cancer, sickle-cell disease (e.g., resulting in persistent
body pain, persistent limb pain, avascular necrosis, persistent abdominal pain), persistent orthopedic pain (e.g.,
spinal injury, spinal disc herniation, persistent limb/stump pain, major trauma), juvenile rheumatoid arthritis (pain
not controlled by therapy treating the underlying disease), and cystic fibrosis resulting in persistent chest pain.
• Patients must have a parent/caregiver who is willing and able to be compliant with the protocol, capable of
patient evaluation, able to read and understand questionnaires, willing and able to use a diary, and able to read,
understand, and sign the written informed consent.
Exclusion criteria:
• Patients who are allergic to buprenorphine or have a history of allergies to other opioids (this criterion does
not include patients who have experienced common opioid side effects [e.g., nausea, constipation]).
• Patients who have allergies or other contraindications to TD delivery systems or patch adhesives.
• Patients with a dermatological disorder at any relevant patch application site that would preclude proper
placement and/or rotation of BTDS patches.
• Patients with evidence of impaired renal function, hepatic impairment, a history of seizures, a history of sleep
apnoea within the past year, unstable respiratory disease, structural heart disease or a pacemaker, or clinically
unstable cardiac disease;
• Patients who, in the opinion of the investigator, are unsuitable to participate in this study for any reason.
• Patients who receive or anticipate to receive investigational medication/therapy during study drug treatment
period.
Other protocol-specific inclusion/exclusion criteria may apply
Interventions Buprenorphine TD system 2.5 mcg/h, 5 mcg/h, 10 mcg/h or 20 mcg/h applied transdermally for 7-day wear
Outcomes • The number of participants with adverse events as a measure of safety (4 weeks).
• Pharmacokinetics of buprenorphine following TD administration (Day 1, week 1, Day 9/10, week 2, and
week 3), including the apparent Vd (volume of distribution) and apparent CL (systemic clearance) of
buprenorphine following TD administration.
• “Pain Right Now” Score (Daily).
• Parent/caregiver-assessed Global Impression of Change (Week 4).
Notes Location: USA.
Sponsors: Purdue Pharma LP.
Principal investigators/contact: Eduardo Rodenas, MD; 203-588-7660; email Eduardo.Rodenas@pharma.com
Target enrolment: N = 40.
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Study starting date: July 2011.
Study completion date: June 2015.
Other study ID numbers: BUP3031, 2010-021954-21.
Ripamonti 1987
Methods “The objective of this study was to compare the analgesic effect over the quality of analgesic relief and side effects of
the two drugs.” (Google translate on 24 July 2014)
Participants “Twenty-five patients suffering frompainful advanced cancer were given intramuscular injections of 0,3mg buprenor-
phine and 10 mg morphine, the second 24 hours after the first.”
Interventions See cell above.
Outcomes “The following parameters were examined: 1) intensity of pain; 2) relief from pain; 3) side effects; 4( vital signs (pulse,
respiration, blood pressure).”
Notes The study is published in Italian and translation of the article has revealed no mention about allocation to treatment
beyond the description of the study as “double-blind cross-over”. It is thus uncertain whether drug administration
was in a random or fixed order
Staquet 1990
Methods Double-blind, parallel-group (3 groups), double-observer comparison of multiple dose regimen of IM ketorolac (10
mg, 30 mg) and buprenorphine (0.3 mg) in patients with cancer pain
Participants 120 patients with moderate-severe cancer pain.
Interventions IM ketorolac (10 mg, 30 mg) and buprenorphine (0.3 mg) for 3 days, administered by a nurse (who was not involved
in the evaluation of the results) as required by the patients
Outcomes Patients rated pain severity andpain relief on a standard verbal scale. “Patterns of usage, duration of efficacy, acceptance,
side-effects, global evaluation were also investigated at preselected times.”
Notes Location: Belgium.
Published as an abstract only. Unclear if treatment group assignment was randomised
Wallenstein 1982
Methods Clinical analgesic assays of buprenorphine andmorphine: “Limited crossover, randomized, double-blind comparisons.
”
Participants Inclusion criteria: “Hospitalized patients with postoperative or cancer pain”.
Exclusion criteria: None reported.
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Interventions “An assay consisting of five sequentially graded dose comparisons of intramuscular buprenorphine and morphine
was carried out in 136 patients. In a second assay, graded sublingual doses of buprenorphine were compared with
intramuscular morphine in a single six-point assay in 150 patients.”
Outcomes Hourly subjective reports of pain and pain relief.
Notes Location: USA.
Sponsors: “Suported in part by NIDA grant DA-01707, NCI core grant CA-08748, and a contribution fromReckitt
and Colman, Ltd.”
Published as abstract only.
Population composition unclear.
Characteristics of ongoing studies [ordered by study ID]
2008-002273-12
Trial name or title Long term opioid administration in oncologic chronic pain: open label, prospective study on efficacy, safety
and pharmacogenetic factors
Methods Randomised, parallel-group, open controlled trial.
Participants Inclusion criteria:
• Age > 18 years.
• Oncologic, chronic, neuropathic or nociceptive peripheric pain or both.
Exclusion criteria:
• Abuse history.
• Opioid analgesic use history.
• Opioid allergies.
Interventions • Morphine (oral solution)
• Morphine (oral tablet)
• Oxycodone (oral tablet)
• Fentanyl (TD patch)
• Buprenorphine (TD patch)
• Hydromorphone (prolonged-release oral tablet)
Outcomes Pain reduction at least 40% in VAS scale.
Starting date Not reported.
Contact information Location: Italy.
Sponsors: Ospedale Policlinico S. Matteo.
Principal investigators: Not reported.
Notes Target enrolment: N = 320.
Study completion date: Unknown but of 3-year duration.
Other study ID numbers: None reported, but is it the same as NCT00916890 below?
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Trial name or title A double-blind, multi-centre, reference-controlled, randomised Phase III study to compare the analgesic
efficacy and tolerability of a buprenorphine transdermal system in two different application intervals using
three different dosages (35, 52.5 or 70 µg/h) in patients with chronic, severe cancer pain inadequately
controlled with other analgesics
Methods Randomised (parallel group), double-blind controlled trial.
Participants Inclusion criteria:
• The patient is suffering from chronic, severe cancer pain and requires opioid treatment.
• The patient is aged between 18 and 75 years.
• The patient is capable of giving informed consent, which includes compliance with the requirements
and restrictions listed in the consent form.
Exclusion criteria:
• Clinically relevant increasing daily doses of the non-opioid and opioid analgesic medication in the last
14 days prior to the start of the study and in the course of the study.
• Intake of any other strong opioids (step 3 WHO-Guidelines) in the course of the study.
• Clinically relevant increasing daily doses of co-analgesics, e.g., steroids, anticonvulsants and
antidepressants in the last 14 days prior to the start of the study and in the course of the study.
• Non-pharmacological pain therapies, e.g., neurolysis, acupuncture, epidural anaesthesia.
• Planned surgery in the next 30 days or in the last 14 days prior to the start of the study.
• Any treatment which in the opinion of the responsible physician might have a clinically relevant
influence on pain intensity
• Patients with clinically significant impaired renal or hepatic function.
• Patients with a clinically relevant impairment of respiratory function including presence or history of
chronic obstructive lung disorder or any other serious lung disease.
• Pregnancy or lactation.
• Women with child-bearing potential who do not apply a medically accepted safe method of
contraception (e.g., sterilisation, oral contraception).
• Known alcoholism or drug abuse.
• Patients with a known or suspected history of abuse of centrally acting substances.
• Patients with increased intracranial pressure including metastases in the CNS which could lead to
respiratory depression.
• Present febrile state and regionally increased body temperature which could lead to increased plasma
concentrations of buprenorphine.
• The subject or his family has a history of non-allergic drug reactions, of a drug allergy, or other allergy,
which in the opinion of the responsible physician contraindicates the subject’s participation in the study.
• The subject has a known or suspected personal history or family history of adverse reactions or
hypersensitivity to buprenorphine or buprenorphine-like substances.
• Treatment with monoamine oxidase inhibitors in the last 14 days prior to the start of the active
treatment phase.
• Patients suffering from myasthenia gravis.
• Significant skin lesions on arms (or other chosen area for patch application) or diffuse skin disease (e.g.
, diffuse psoriasis or eczema).
• Subjects with a medical disorder, condition or history of such that would impair the subject’s ability to
participate or complete this study in the opinion of the investigator.
• Participation in another clinical trial within one month prior to enrolment or during the course of the
study.
• Relevant pathological changes in the ECG.
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2008-003592-48 (Continued)
Interventions • Buprenorphine (TD patch applied every 96 hours).
• Buprenorphine (TD patch applied every 72 hours).
Main objective: Primary objective of the study is to demonstrate that the BUP-TDS applied every 96 hours
(Treatment group A) is therapeutically non-inferior to BUP-TDS applied every 72 hours (Treatment group
B)
Primary end point(s): To assess and compare the analgesic efficacy and tolerability of a buprenorphine TD
system in two different application intervals using three different dosages (35, 52.5, or 70 µg/h)
Outcomes • Assessment of pain intensity during the day (8 am to 8 pm) and at night (8 pm to 8 am) with a 11-
point numeric rating scale in each treatment group.
• Calculation of the mean number of SL tablets required as rescue medication.
• Calculation of the mean number of SL tablets required as rescue medication per day during the active
treatment phase compared with the daily demand during the run-in phase in each treatment group.
• Duration of sleep undisturbed by pain in each treatment group.
• Assessment of safety and tolerability characteristics of BUP-TDS by measuring the frequency, severity,
and type of adverse event.
• Assessment of dermal tolerability and adhesive properties of BUP-TDS by the Skin Irritation Score
and the Adhesion Score (see Section 14.1 Scoring systems).
Starting date 25 November 2008.
Contact information Location: Bulgaria.
Sponsors: Novosis AG.
Principal investigators: Not reported.
Notes Target enrolment: N = 100.
Study completion date: Not reported.
Other study ID numbers: EUCTR2008-003592-48-BG, BUP/006/C.
NCT00916890
Trial name or title Chronic Administration of Opioids in Cancer Chronic Pain:an Open Prospective Study on Efficacy, Safety
and Pharmacogenetic Factors Influence
Methods Randomised (parallel group), single-blind (outcome assessor) controlled trial
Participants Inclusion criteria:
• Adult oncologic patients (≥ 18 years old).
• Chronic peripheral neuropathic and/or nociceptive pain.
• Written informed consent.
Exclusion criteria:
• Pediatric patients.
• Mental impaired patients.
• Substance abuse disorder.
• Opioid allergy.
• History of opioids use or addiction.
• Severe immunodeficiency, severe renal impairment, severe liver disease.
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NCT00916890 (Continued)
• Cachectic state.
• HIV positive patients.
Interventions • Morphine (after a titration phase with fast-release oral morphine, once the optimal dosage (no side
effects and less than two rescue doses per day) is reached, an equipotent dose of oral sustained-release
morphine will be randomly assigned to a patient).
• Oxycodone (after a titration phase with fast-release oral morphine, once the optimal dosage (no side
effects and less than two rescue doses per day) is reached, an equipotent dose of oral extended-release
oxycodone will be randomly assigned to a patient).
• Fentanyl (after a titration phase with fast-release oral morphine, once the optimal dosage (no side
effects and less than two rescue doses per day) is reached, an equipotent dosage of TD fentanyl will be
randomly assigned to a patient).
• Buprenorphine (after a titration phase with fast-release oral morphine, once the optimal dosage (no
side effects and less than two rescue doses per day) is reached, an equipotent dosage of TD buprenorphine
will be randomly assigned to a patient).
Outcomes Primary outcomes:
• To identify the drug with the best clinical-pharmacological safety-efficacy profile among the four
opioids: oral extended-release morphine, oral extended-release oxycodone, TD fentanyl and TD
buprenorphine. Time Frame: 15 days after randomisation (Reduction of at least 40% of median daily pain,
on a NRS).
“We will define a treatment effective if it will produce a mean reduction of NRS values at least of 40% than
basal values. Among all effective treatments, we will identify the best as the one that will have a reduction of
NRS to a value of 4 or less in 90% of patients compared to the 70% of the others treatments. To evaluate
pharmacological safety the plasma concentrations of the drugs and their metabolites will be measured.We will
branch patients population in 3 groups to evaluate the correlation between clinical-pharmacological response
and genetics (responder,partially and not responder).”
Secondary Outcome Measures:
• Pharmacokinetic of opioids and of their metabolites during long-term administration; correlation
between specific genotypes and clinical response or the clinical/pharmacological susceptibility to side-effects
on administration of a specific opioid. Time Frame: 6 months (each patient will be followed for 6 month
after enrolment with clinical/pharmacological evaluations once a month and if inefficacy, tolerance or side
effects).
• Comparison of plasma levels of opioids and of their metabolites in “responder” patients (clinical
effectiveness without side effects), “partially responders” patients (clinical effectiveness without side effects
but taking not more than 2 rescue doses per day), and in “non responder” patients (3 groups: clinical un-
efficacy, side-effects, tolerance and/or opioid induced hyperalgesia). Evaluation of the correlation between
the polymorphisms studied and clinical response; the frequency of allelic variants of interest will be
compared in “responder”, “partially responder” and “non responder”.
Starting date February 2009.
Contact information Location: Italy.
Sponsors/collaborators/investigators : IRCCS Policlinico S. Matteo, University of Pavia, Italy
Principal investigator: Massimo Allegri, IRCCS Foundation Policlinico “San Matteo”, Pavia, Italy; email:
m.allegri@smatteo.pv.it , Tel: 00390382502627.
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NCT00916890 (Continued)
Notes Target enrolment: N = 320.
Study completion date: December 2015.
Other study ID numbers: PT-SM-1-Op-Cancer.
NCT01809106
Trial name or title RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids
(Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the
Moment of Starting 3rd Step of WHO Analgesic Ladder
Methods Randomised (parallel? cross-over?), open-label controlled trial
Participants Inclusion criteria:
• Patients with diagnostic (histological or cytological) evidence of locally advanced or metastatic solid
tumour;
• Average pain intensity ≥ 4, measured with NRS and related to the last 24 hours, due to the cancer,
requiring for the first time an analgesic treatment with 3rd step/WHO opioids.
• Life expectancy > one month.
• “strong” opioid naïve.
• Eligible to take any of the medications under evaluation, by TDS or by mouth.
• Age ≥ 18 years.
Exclusion criteria:
• Patients recruited in other researches that conflict or may confound the conduction and results of the
present study;
• Lack of informed consent.
• With presence of other diseases, including psychiatric/mental illness, severe senile or other form of
dementia, that can interfere with participation and compliance with the study protocol or can
contraindicate the use of the investigational drugs;
• With presence of co-morbidities, which could create potentially dangerous drug interactions with
opioids (e.g., use of macrolide antibiotics or antifungal….).
• Any kind of contraindications to the use of opioid drugs.
• With a known story, past or current, of drugs abuse or addiction.
• Use of drugs which presents a combination of opioids and other molecule (as NSAIDs, paracetamol,
naloxone...).
• Who cannot guarantee regular follow-up visits for logistic or geographic reasons.
• Need of starting 3rd step treatment in an “emergency clinical situation” that do not allow the correct
procedures of randomisation.
• Diagnosis of primary brain tumour or leukaemia.
• Diagnosis of chronic renal failure.
• Patients with antalgic radiotherapy or radio-metabolic therapy in progress or completed less than 14
days before study;
• Patients starting a first line chemotherapy simultaneously to the beginning of the study.
• Other types of analgesic treatments, including local-regional anaesthetic techniques or neurosurgical /
ablative methods.
Interventions • Morphine (60 mg/24 hours).
• Oxycodone (40 mg/24 hours).
• Buprenorphine (35 µg/hour).
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NCT01809106 (Continued)
• Fentanyl (25 µg/hour)
.
Outcomes Primary outcomes:
• Proportion of Non-Responder (NR) patients. Time frame: 28 days.
• Evaluation of the proportion of Non-Responder (NR) patients. NR correspond to the subjects who do
not report any analgesic effects, with a P.I.D. (pain intensity difference) from visit 6 and visit 1 ≤ 0%,
(using a 0-10 NRS ). It includes the situations of average pain intensity “stable” or “worsened” at day 28
compared with baseline values.
Secondary outcomes:
• Proportion of full-responder. Time frame: 28 days.
• Evaluation of the proportion of subjects who report full analgesia (full responders: FR). FR is
operationally defined as a patient with a P.I.D. ≥ 30% from visit 6 and visit 1 (NRS 0 to 10).
Other outcomes:
• The opioid escalation index. Time frame: 28 days.
• The proportion of subjects with an increase of opioid daily dose > 5% compared with the basal dosage
(OEI%).
Starting date April 2011.
Contact information Location: Italy.
Sponsors/collaborators: Mario Negri Institute for Pharmacological Research
Principal investigator: Oscar Corli, MD. Mario Negri Institute of Pharmacological Research - IRCCS
Contact: oscar.corli@marionegri.it; anna.roberto@email.it
Notes Target enrolment: N = 600.
Study completion date: April 2014.
Other study ID numbers: None reported.
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. SL buprenorphine comparisons: Adverse events
AE SL Bup ver-
sus SD Bup
SL Bup ver-
sus oral ti-
lidin-HCI
+ naloxone-
HCI
SL Bup versus oral Tra SL Bup versus SL
Bup + oral P versus
oral P
SL
Bup versus
oral Pen
Bup tablets/fluid versus
Pen Tab/F
Limón
Cano 1994
Bauer 1985 Bono 1997 Brema
1996
Yajnik 1992 De Conno
1987a
Dini 1986
SL
bup
SD
bup
SL
bup Til+Na
SL
bup
Tra SL
bup
Tra Bup Bup
+ P
P SL
bup
Pen Bup
tablets
Bup
fluid
Pen
tablets
Pen
fluid
Any
AEs
34/
60
9/60 16/
63
17/
68
13/
25
5/25 2/25 18% 50%
To-
tal
AEs
49 9
Ab-
dom-
inal
pain
0.6 1
Acid-
ity
0.5 1
Agi-
ta-
tion
2 2.4 0/11 0/11 0/10 2/10
Al-
lergy
0.1 0.2
Anorexia/
ap-
petite
loss
1/60 0/60
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Table 1. SL buprenorphine comparisons: Adverse events (Continued)
Blood
loss
0.1 0.1
Brady-
car-
dia
3/25 1/25 0/25
Con-
fu-
sion
0/11 0/11 0/10 1/10
Con-
sti-
pa-
tion
Bup =
Til+Na
4/60 2/60 3/63 4/68
Dizzi-
ness/
con-
fu-
sion
6/60 1/60 3/63 4/68 1.1 2
Drowsi-
ness/
som-
no-
lence
14/
60
5/60 5/63 7/68 4/25 1/25 0/25 2.7 2.2 0/11 2/11 3/10 1/10
Dry
mouth
1/60 0/60 2.8 2.6
Fa-
tigue
Bup =
Til+Na
Gid-
di-
ness
0/25 0/25 1/25
Hal-
luci-
na-
tions
3/10 5/7 1/60 0/60
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Table 1. SL buprenorphine comparisons: Adverse events (Continued)
Headache
0/25 0/25 1/25 0.9 1.1
Heart-
burn
0.6 0.9
Heavy
head
1/60 0/60
Hic-
cup
1/60 0/60
Hy-
poten-
sion
1/25 1/25 0/25
Irri-
tabil-
ity
1/60 0/60
Nau-
sea
Bup =
Til+Na
8/60 0/60 7/63 8/68 1.4 1.6
Nau-
sea
and
vom-
iting
SL =
SD
SL =
SD
6/60 0/60 2/25 1/25 0/25
Pru-
ritus
1.1 0.7
Res-
pira-
tory
de-
pres-
sion
1/10 1/7 3/25 1/25 0/25
Se-
da-
tion
SL =
SD
SL =
SD
Sweat-
1/60 0/60 2.4 2.1
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Table 1. SL buprenorphine comparisons: Adverse events (Continued)
ing
Thirst
Tremors
1.1 1.7
Vom-
iting
Bup =
Til+Na
6/60 1/60 1.1 0.8 2/11 2/11 2/10 0/10
Dis-
con-
tinu-
a-
tion
due
to
AE
0 0 19/
60
2/60 7/63 6/68
Abbreviations: AE = adverse events; SL = sublingual; SD = subdermal; Bup = buprenorphine; P = phenytoin; Pen = pentazocine; SC =
subcutaneous; SD = subdermal; SL = sublingual; Tab = tablets; Til+Na = tilidin + naloxone; Tra = tramadol; F = fluid.
aAverage.
Table 2. Transdermal buprenorphine comparisons: Adverse events
AE TD Bup versus placebo TD Bup ver-
sus
controlled-
release Mor
TD Bup ver-
sus TD Fen
Böhme 2003 Poulain
2008
Sittl 2003 Sorge 2004 Pace 2007 Sarhan 2009
Placebo
35
µg/h
Bup
52.5
µg/h
Bup
70
µg/h
Bup
Placebo
70
µg/h
Bup
Placebo
35
µg/h
Bup
52.5
µg/h
Bup
70
µg/h
Bup
Placebo
35
µg/h
Bup
TD
Bup
CR
Mor
TD
Bup
TD
Fen
At
least
one
AE
28/
38
35/
41
33/
41
28/
37
As-
the-
nia
1/95 4/94
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Table 2. Transdermal buprenorphine comparisons: Adverse events (Continued)
Cen-
tral
ner-
vous
sys-
tem
AE
20/
38
23/
41
19/
41
20/
37
Con-
fu-
sion
1/26 1/26
Con-
stipa-
tion
2/95 9/94 2/26 10/
26
Dizzi-
ness/
con-
fu-
sion
0/95 0/94
Drowsi-
ness/
som-
no-
lence
3/26 2/26 Bup
> Fen
Bup
> Fen
Ery-
thema
7/38 12/
41
12/
41
12/
37
0/19
a
0/26
a
Ex-
an-
thema
0/37
a
0/35
a
1/41
a
0/38
a
1/38 5/41 5/41 1/37
Fa-
tigue
2/95 0/94
Gas-
troin-
testi-
nal
AE
26.
30%
17.
10%
36.
60%
43.
20%
Headache
3/26 4/26
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Table 2. Transdermal buprenorphine comparisons: Adverse events (Continued)
Nau-
sea
7/95 3/94 3/26 9/26
Pru-
ritus
0/37
a
0/35
a
3/41
a
1/38
a
9/38 10/
41
11/
41
9/37 0/19
a
0/26
a
Skin
com-
plica-
tion,
local
Bup
> Fen
Bup
> Fen
Swelling,
non-
in-
flam-
ma-
tory
1/38 1/41 0/41 0/37
Ver-
tigo
3/26 11/
26
Vom-
iting
6/95 5/94
Dis-
con-
tinu-
ation
due
toAE
6/95 1/94 6/38 3/41 5/41 3/37
Abbreviations: Bup = buprenorphine; F = fluid; Fen = fentanyl; IM = intramuscular; Mor =morphine; P = phenytoin; Pen = pentazocine;
Pla = placebo; SC = subcutaneous; SD = subdermal; SL = sublingual; Sup = suppository; Tab = tablets; Til+Na = tilidin + naloxone;
Tra = tramadol.
aSevere.
Table 3. Single study comparisons: Adverse events
AE IMBup versus Bup Sup IM Bup versus IM
Mor
IM Bup + SC Bup versus SC Bup
versus placebo + SC Bup
Epi Bup versus Epi Mor
Dan 1989a Kjaer 1982 Noda 1989 Pasqualucci 1987
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Table 3. Single study comparisons: Adverse events (Continued)
IM Bup Sup Bup IM Bup IM Mor IM + SC
Bup
SC Bup Placebo +
SC Bup
Epi Bup Epi Mor
Local toxi-
city/ab-
normal ef-
fect at in-
jection/in-
fusion site
0/10 0/10 0/10
Total AEs 21.80 ± 3.
67
11.41 ± 1.
75
80 54
Anorexia/
appetite
loss
9/31 8.5/32.5
Anxiety 1/26 0/26
Blurred vi-
sion
3/26 0/26
Chest pain 0/10 0/10 0/10
Decreased
memory
1/26 2/26
Deep res-
piration
1/26 0/26
Depres-
sion
0/10 0/10 0/10
Dizziness/
confusion
1.63 ± 0.
53
0.24 ± 0.
09
18/26 7/26 2/6 0/6
Drowsi-
ness/som-
nolence
5.29 ± 0.8 3.44 ± 0.
56
0/10 2/10 1/10 1/6 0/6
Drunken
feeling
1/26 0/26
Eruption 0/10 0/10 0/10
Euphoria 2.09 ± 0.
54
2.09 ± 0.
56
5/26 5/26
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Table 3. Single study comparisons: Adverse events (Continued)
Fatigue 0.69 ± 0.
43
0.26 ± 0.
17
1/10 0/10 0/10
Hallucina-
tions
0/10 0/10 1/10
Headache 2/26 1/26
Heavy
head
1.83 ± 0.
53
0.91 ± 0.
31
Hypoten-
sion
0/10 0/10 0/10
Nausea 2.89 ± 0.
63
1.29 ± 0.
43
11/26 4/26 0/10 0/10 2/10 3/6 1/6
Numb-
ness, hand
and feet
0/26 1/26
Palpitation 0/10 0/10 0/10
Pruritus 0/10 0/10 1/10 0/6b 2/6b
Remote
feeling
0/26 1/26
Respi-
ratory de-
pression
0/10 0/10 0/10
Sedation 14/26 18/26
Sweating 1.31 ± 0.
47
0.79 ± 0.
32
10/26 3/26
Thirst 1.94 ± 0.
53
0.71 ± 0.
24
2/26 7/26
Urinary re-
tention
1.94 ± 0.
72
0.91 ± 0.
41
0/10 0/10 0/10
Vertigo 0/10 0/10 3/10
Vomiting 2.20 ± 0.
53
0.68 ± 0.
21
11/26 5/26 0/10 0/10 1/10 2/6 1/6
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Table 3. Single study comparisons: Adverse events (Continued)
Discontin-
uation due
to AE
7/35 1/34
Abbreviations: Bup = buprenorphine; Fen = fentanyl; IM = intramuscular; Epi = epidural; Mor = morphine; SC = subcutaneous; SD
= subdermal; SL = sublingual; Sup = suppository; Tab = tablets; Til+Na = tilidin + naloxone; Tra = tramadol.
aAverage.
bOf the face.
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL
#1 MeSH descriptor: [Buprenorphine] this term only
#2 buprenorphine:ti,ab,kw (Word variations have been searched)
#3 (magnogen or temgesic or subutex or transtec or anorfin or bupren or norphin or pentorel or tidigesic or nopan or finibron or
brospina or temgesic-nX or buprex or prefin or suboxone or buprenex or buprine or butrans):ti,ab,kw (Word variations have been
searched)
#4 #1 or #2 or #3
#5 MeSH descriptor: [Pain] explode all trees
#6 (pain* or nocicept* or neuropath*):ti,ab,kw (Word variations have been searched)
#7 #5 or #6
#8 MeSH descriptor: [Neoplasms] explode all trees
#9 (cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk?emia* or metasta* or
malignan* or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog*):ti,ab,kw (Word variations have been searched)
#10 #8 or #9
#11 #4 and #7 and #10
MEDLINE
1. Buprenorphine/
2. buprenorphine.tw.
3. (magnogen or temgesic or subutex or transtec or anorfin or bupren or norphin or pentorel or tidigesic or nopan or finibron or
brospina or temgesic-nX or buprex or prefin or suboxone or buprenex or buprine or butrans).tw.
4. or/1-3
5. exp Pain/
6. (pain* or nocicept* or neuropath*).tw.
7. 5 or 6
8. exp Neoplasms/
9. (cancer$ or neoplas$ or tumo$ or carcinoma$ or hodgkin$ or nonhodgkin$ or adenocarcinoma$ or leuk?emia$1 or metasta$ or
malignan$ or lymphoma$ or sarcoma$ or melanoma$ or myeloma$ or oncolog$).tw.
10. 8 or 9
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11. 4 and 7 and 10
12 randomized controlled trial.pt.
13 controlled clinical trial.pt.
14 randomized.ab.
15 placebo.ab.
16 drug therapy.fs.
17 randomly.ab.
18 trial.ab.
19 or/12-18
20 exp animals/ not humans.sh.
21 19 not 20
22 11 and 21
EMBASE
1. Buprenorphine/
2. buprenorphine.tw.
3. (magnogen or temgesic or subutex or transtec or anorfin or bupren or norphin or pentorel or tidigesic or nopan or finibron or
brospina or temgesic-nX or buprex or prefin or suboxone or buprenex or buprine or butrans).tw.
4. or/1-3
5. exp Pain/
6. (pain* or nocicept* or neuropath*).tw.
7. 5 or 6
8. exp Neoplasms/
9. (cancer$ or neoplas$ or tumo$ or carcinoma$ or hodgkin$ or nonhodgkin$ or adenocarcinoma$ or leuk?emia$1 or metasta$ or
malignan$ or lymphoma$ or sarcoma$ or melanoma$ or myeloma$ or oncolog$).tw.
10. 8 or 9
11. 4 and 7 and 10
12. random$.tw.
13. factorial$.tw.
14. crossover$.tw.
15. cross over$.tw.
16. cross-over$.tw.
17. placebo$.tw.
18. (doubl$ adj blind$).tw.
19. (singl$ adj blind$).tw.
20. assign$.tw.
21. allocat$.tw.
22. volunteer$.tw.
23. Crossover Procedure/
24. double-blind procedure.tw.
25. Randomized Controlled Trial/
26. Single Blind Procedure/
27. or/12-26
28. (animal/ or nonhuman/) not human/
29. 27 not 28
30. 11 and 29
BIOSIS & Web of Science
# 13 #12 AND #6
# 12 #11 AND #10
# 11 TOPIC: (((human*)))
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# 10 #9 OR #8 OR #7
# 9 TOPIC: ((((singl* OR doubl* OR trebl* OR tripl*) SAME (blind* OR mask*))))
# 8 TOPIC: (((controlled clinical trial OR controlled trial OR clinical trial OR placebo)))
# 7 TOPIC: (((randomised OR randomized OR randomly OR random order OR random sequence OR random allocation OR
randomly allocated OR at random OR randomized controlled trial)))
# 6 #5 AND #4 AND #3
# 5 TOPIC: ((cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk?emia* or metasta*
or malignan* or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog*))
#4 TOPIC: ((pain* or nocicept* or neuropath*))
#3 #2 OR #1
# 2 TOPIC: ((magnogen or temgesic or subutex or transtec or anorfin or bupren or norphin or pentorel or tidigesic or nopan or finibron
or brospina or temgesic-nX or buprex or prefin or suboxone or buprenex or buprine or butrans))
# 1 TOPIC: (buprenorphine)
Trial registers
ClinicalTrials.gov, WHO ICTRP, Current Controlled Trials (inc mRCT), and Proceedings of the Congress of the European
Federation of International Association for the Study of Pain (IASP) (via European Journal of Pain Supplements):
(magnogen or temgesic or subutex or transtec or anorfin or bupren or norphin or pentorel or tidigesic or nopan or finibron or brospina
or temgesic-nX or buprex or prefin or suboxone or buprenex or buprine or butrans)
AND
(cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk?emia* or metasta* or malignan*
or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog*)
WH A T ’ S N E W
Last assessed as up-to-date: 21 January 2015.
Date Event Description
10 November 2016 Amended Contact details updated.
17 October 2016 Review declared as stable See Published notes.
H I S T O R Y
Protocol first published: Issue 1, 2012
Review first published: Issue 3, 2015
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Date Event Description
16 June 2015 Amended Minor changes made to wording in Abstract.
17 May 2013 New citation required and major changes New citation: major change. This protocol has been significantly up-
dated by new authors. See Published notes.
C O N T R I B U T I O N S O F A U T H O R S
MSH andMT conceived, designed and wrote the review. MSH coordinated the review and devised the analysis strategy. The Cochrane
PaPaS Group and SA devised and executed the search strategy. MSH and JH screened the search results, and appraised and extracted
data from the included studies. MSH and MT wrote the review, and all review authors approved the final version of the review.
D E C L A R A T I O N S O F I N T E R E S T
Mia Schmidt-Hansen has no conflicts of interest to declare.
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Mark Taubert has no conflicts of interest to declare.
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S O U R C E S O F S U P P O R T
Internal sources
• None, Other.
External sources
• None, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
It was originally planned that we would also search CINAHL and PubMED, however we did not search these databases as it was felt
(in consultation with PaPaS) that this level of database searching was not required. In this respect, it was noted that:
1. CINAHL is a nursing database and is therefore unlikely to yield anything extra that will meet the inclusion criteria; and
2. There is a great deal of overlap between MEDLINE and PubMED. Therefore, generally one or the other is searched, which was
MEDLINE in our case.
In the protocol we stated that two review authors would perform all data extractions from the included studies. However, we only
performed double-reviewing for the studies published in full in English and not for those published as an abstract only or those requiring
translation by translators either external or internal to the review author team.
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The structure of the ’Summary of findings’ table differs from that planned at protocol stage. We felt that the chosen format gave a
clearer summary given the nature of the included data and the number of different comparisons.
N O T E S
This protocol was originally published in Issue 1, 2012 (Naing 2012). The authors of the 2012 protocol were unable to complete the
full review and it was withdrawn in April 2013. The current author team of the new protocol completed the full review instead.
AtNovember 2016, this review has been stabilised. A search in September 2016 did not identify any potentially relevant studies likely to
change the conclusions. Therefore, this review has now been stabilised following discussion with the authors and editors. If appropriate,
we will update the review if new evidence likely to change the conclusions is published, or if standards change substantially which
necessitate major revisions.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Cutaneous; Administration, Oral; Administration, Sublingual; Analgesics, Opioid [administration & dosage;
∗therapeutic use]; Buprenorphine [administration & dosage; ∗therapeutic use]; Neoplasms [∗complications]; Pain [∗drug therapy;
etiology]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Child; Humans
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